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”Den enda sanna visheten är att veta att du egentligen inte vet någonting”  
– Sokrates 
  

ABSTRACT 
Side effects due to chemotherapy is still a major issue during cancer treatment. Febrile neutropenia 
and associated microbiological defined infections (MDIs) are dreaded complications, and still a cause 
of death during pediatric cancer treatment. In many of the febrile neutropenia episodes the cause of the 
fever is unknown, and risk factors of developing febrile neutropenia are poorly characterized. To be 
able to pin-point children at risk of febrile neutropenia and anticipate those at risk of more severe 
episodes could lead to more individualized treatment. Therefore, the aim of this thesis was two-fold: 
to investigate the microbiological causes of febrile neutropenia episodes and to investigate risk factors 
of developing this condition and associated MDIs.  
   In papers I and IV, causes of febrile neutropenia episodes were assessed. In paper I, we identified 
a respiratory virus in 45% of the episodes, which was in line with earlier reports. In addition, follow-
up nasopharyngeal sampling showed that only rhinovirus and coronavirus were persistent and all other 
viruses cleared from the nasal cavity. This indicated that the respiratory virus identified was indeed the 
cause of the fever. However, causality could not be established. Therefore, paper IV investigated the 
innate immune response during these episodes. By using gene-expression profiling, the aim was to 
investigate specific innate signatures in blood. Unfortunately, due to the immunosuppression, there 
was insufficient RNA from ~30% of the samples and a specific innate signature, similar to that of 
immunocompetent children, could not be identified. Therefore, the feasibility of using gene-
expression profiling to correlate the microbiological findings to an active infection and as a diagnostic 
tool in children treated for cancer remains challenging.  
   In papers II and III, risk factors of developing neutropenia and febrile neutropenia with associated 
MDI and low end doses of 6-Mercaptopurine (6-MP) during pediatric ALL treatment were addressed. 
In paper II, genetic variants in important enzymes involved in drug metabolism were investigated. 
Here, TPMT genetic variants were associated with a decreased risk of developing neutropenia and 
febrile neutropenia during the maintenance II period, and deficiency in ITPA (rs1127345) to a 
decreased risk of developing febrile neutropenia (unadjusted). In addition, genetic variants in 
NUDT15 were associated with decreased end doses of 6-MP. From the results from paper II, we 
could still not fully understand the role of TPMT and ITPA and the risk of febrile neutropenia. In 
addition, NUDT15 seem to play an important role for the 6-MP doses. However, due to the small 
samples sizes, our results need further investigation in larger cohorts. In paper III, the febrile 
neutropenia episodes were characterized and genetic variants in important innate immune proteins 
were investigated. Viral infections were the most common detected infection during febrile 
neutropenia episodes. However, in the majority of the episodes the cause of the fever remained 
unknown. TLR4 genetic variants increased the risk of viral infections and variants in the IL-1Ra gene 
decreased the risk of developing bacterial bloodstream infection. There were no association between 
MBL and the investigated genetic variants. Therefore, TLR4 and IL-1Ra seem to have a role during 
infectious episodes in children treated for cancer, however, the results needs to be confirmed in future 
studies.   
   In conclusion, respiratory virus are common during febrile neutropenia. However, additional more 
sensitive methods are needed to be able to identify and prove causality between the microbiological 
findings and the febrile neutropenia episode. Some of the investigated genetic variants seem to play a 
role in the risk of developing febrile neutropenia and infections. However, some of these need to be 
further evaluated before any modifications of the management of febrile neutropenia could be 
recommended. 
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1 BACKGROUND 
1.1 PEDIATRIC CANCER  
Cancer in children is relatively rare in Sweden, with approximately 350 cases annually (1, 2). 
Pediatric cancers span over diverse clinical and biological tumour entities, including leukaemia and 
lymphoma, bone and soft tissue sarcoma, central nervous system tumours, retinoblastoma, 
neuroblastoma, liver and kidney tumours, germ cell tumours and additional rare cancers. There is an 
emerging concept suggesting that epigenetic dysregulation is central to many forms of childhood 
cancer and that many pediatric tumours arise from stem- or progenitor cells during particular 
developmental time frames (3, 4). In recent decades, the survival rate has increased considerably and 
the 5-year survival is currently 80–85% (2, 5, 6). Leukemia, is the most common cancer diagnosed in 
children, accounting for ~30% of the cases, which mainly includes acute lymphoblastic leukemia 
(ALL) (~80%) and Acute myeloid leukemia (~20%), followed by brain tumors (30%) and lymphomas 
(10%) (6).  
   The cornerstones of pediatric cancer treatment are chemotherapy, radiation, and surgery while 
immunotherapy is an emerging treatment modality. The treatment regimens have different acute side 
effects, such as neutropenia, that need to be carefully monitored to reduce treatment-related mortality 
and morbidity. Because ALL is the most common diagnosis in in children with cancer, most subjects 
enrolled in the studies included in this thesis were treated for ALL. The protocol for the treatment of 
ALL used in Sweden during the last decades is the Nordic Society for Pediatric Hematology and 
Oncology (NOPHO) ALL treatment protocol.  
 
1.1.1 Chemotherapy treatment 
In pediatric cancers, the malignant cells often exhibit a high proliferation rate and a susceptibility to 
chemotherapy (7). The initial aim of chemotherapy is to achieve remission and later eradication of the 
minimal residual disease (MRD). Chemotherapy can be given as a combination of two or more drugs 
and is administered sequentially to increase the probability of eradicating as many cancer cells as 
possible (7). The type of chemotherapeutic agent depends on the diagnosis, and currently, 
standardized treatment protocols are frequently used for the respective cancers in pediatric patients.  
   There are different classes of chemotherapeutic agents that, depending on the mechanism of action, 
interfere with cell division or cell death in cancer: (i) anti-metabolite compounds, which lead to 
interference with the synthesis of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) (e.g., 6-
mercaptopurin (6-MP)), (ii) anti-folates, which decrease the synthesis of precursor DNA (e.g. 
methotrexate (MTX), (iii) anti-microtubular compounds, which disrupt cellular architecture, (iv) L-
asparaginase, which depletes plasma and intracellular levels of the amino acid asparaginase, (v) 
alkylating agents, which alter DNA and its replication by binding alkyl groups, and (iv) anthracyclines 
which forms free radicals, lipid peroxidation and enzyme interactions (7, 8). Chemotherapy can be 
administered intravenously, intrathecally, per oral (e.g., 6-MP), or intramuscularly.   
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1.1.2 Acute side effects of chemotherapy 
Because chemotherapy is designed to target highly proliferating cells, it also causes cytotoxicity in 
non-malignant host cells, such as hair follicles, epithelial cells of the gut and hematopoietic cells. 
When the gastrointestinal mucosa is affected, inflammation and a disrupted epithelial barrier that 
increases the risk of infection may occur (9). However, one of the most common side effects is bone 
marrow (BM) suppression, resulting in anemia (low red blood cell count), thrombocytopenia (low 
platelets), and neutropenia (low levels of neutrophils). Importantly, chemotherapy affects the 
production of new blood cells and the maintenance of immune memory cells (B and T-cells), thus 
resulting in impaired protection against previously acquired infections (10, 11). 
 
1.1.2.1 Neutropenia 
Myelopoiesis describes the maturation of different blood cells derived from the hematopoietic stem 
cell, leading to the formation of red blood cells, platelets, mast cells, lymphocytes, dendritic cells, 
monocytes/macrophages, and granulocytes (Figure 1). Granulocytes can be grouped into three 
different cell types: basophils, eosinophils, and neutrophils (12) (Figure 1). Neutrophils are the most 
abundant white blood cell (WBC) in the blood, with a concentration of ~2-8 × 109/L and are one of the 
first cell types to respond to infections (12). Neutrophils recognize and ingest microorganisms for 
intracellular killing, a process called phagocytosis. In response to infection, additional immune cells 
(e.g., T cells, macrophages, endothelial cells, and fibroblasts) secrete both interleukins (ILs) and 
granulocyte colony-stimulating factor that act on the BM niche to release mature neutrophils stored in 
the BM and stimulate the proliferation of granulocyte precursors cells (13-15). Therefore, the 
concentration of neutrophils in the blood can increase rapidly upon infection (12). However, 
neutrophils are short lived in the blood (6–9 hours), so it is essential that the BM continuously produce 
new neutrophils (12). Upon chemotherapy, both the storage and new production of neutrophils are 
suppressed. Neutropenia (an absolute neutrophil count (ANC) ≤0.5 × 109/L) is common during cancer 
treatment and is a major risk factor of infections. Neutropenia is also a common reason for delayed 
chemotherapy treatment (16, 17). The lowest neutrophil count usually occurs ~7–10 days after 
previous chemotherapy treatment. Therefore, careful monitoring of the child’s WBC count is 
performed during intensive cancer treatment to detect neutropenia. 
 
1.1.3 Acute lymphoblastic leukemia 
In the vast majority of cases, the cause of the ALL is unknown although a few risk factors are 
associated to ALL, such as Down syndrome and radiation exposure (18-20). ALL arises from genetic 
changes that affect the precursor-stage of B or T lymphoid cells, which further block lymphoid 
differentiation and drives abnormal cell proliferation and monoclonal expansion of immature 
lymphoid cells, leading to a leukemic clone (Figure 1) (21). At diagnosis, the clonal expansion of 
leukemic cells gives rise to BM suppression, leading to pancytopenia. The typical clinical presentation 
of ALL includes pallor, fatigue, fever, bruises/bleeding, enlarged liver and/or spleen, swollen lymph 
nodes, and skeletal pain (7).  
   Childhood ALL includes a number of subtypes defined by cell lineage (B- or T- cell), differentiation 
status and genetic alterations (22). These biological characteristics differ by age distribution and 
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clinical outcome, and are therefore used for tailoring therapy to the predicted risk of relapse. Pre-B 
ALL is the most common phenotype, accounting for ~85–90% of the ALL diagnoses in children (23). 
Currently, phenotype, genetic aberrations and response to therapy is used for ALL risk stratification 
and further treatment (21). The treatment of ALL includes steroids, chemotherapy, and in a few 
children hematopoietic stem cell transplantation (HSCT) may be an option. The standard treatment in 
Sweden has been provided through collaboration with the Nordic countries and the establishment of 
NOPHO ALL treatment protocols (23, 24). 
 
1.1.3.1 NOPHO ALL treatment protocol 
The NOPHO ALL 2000 and 2008 protocols were used between 2000–2008 and 2008–2019, 
respectively. In 2019, a new protocol was implemented through a European collaboration called 
“ALLTOGETHER” and is currently used in the Nordic countries. In the following section, the 
NOPHO ALL 2008 protocol and the differences between the 2000 and 2008 protocols will be 
discussed. In these treatment protocols, chemotherapy dosing was based on body surface area to 
ensure optimal dosing. 
   Within the NOPHO 2008 protocol, ALL treatment was divided into the following phases: induction, 
consolidation, delayed intensification, maintenance, and “block treatment” (only for children in the 
high-risk (HR) group) (Figure 2). At diagnosis, patients were stratified to either HR induction if T-
ALL and/or WBC >100 × 109/L or low-risk induction if pre-B ALL and WBC<100 × 109/L. After a 
new BM sample day 29, additional stratification was performed into risk groups based on (i) response 
to treatment (BM MRD), (ii) leukemic phenotype (pre-B ALL or T cell ALL), (iii) karyotype of the 
leukemic clone, and (iv) presence of leukemic cells in the spinal fluid. The NOPHO ALL-2008 
protocol contains three different risk groups: standard risk (SR), intermediate risk (IR), and HR. 
Additionally, children with poor response could be allocated to HSCT according to specific criteria. 
Lastly, a third stratification was performed after measuring MRD in BM at day 79. Particularly during 
the first 36 weeks of treatment, the HR group differed substantially from that of the SR and IR groups 
(Figure 2). The entire treatment protocol proceeded over a 2.5-year period. 
   There were some differences between the NOPHO ALL 2000 and 2008 protocols: (i) children 
treated within the HR group per the 2008 protocol received more intensive treatment than in the 2000 
protocol and were treated for 2.5 years instead of two years, (ii) there were in general slightly higher 
doses of chemotherapy used per the 2008 as compared to the 2000 protocol. In the 2008 protocol, a 
randomized study involving the doses of 6-MP was performed, and therefore, some children treated 
according to the 2008 protocol may have received higher 6-MP doses (Figure 2), (iii), during the 
maintenance phase, 6-MP/MTX doses were adjusted to a target WBC to 1.5–3.5 × 109/L and 1.5–
3.0 × 109/L (2000 and 2008 protocol, respectively).  
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1.2 INFECTIONS IN CHILDREN  
Infections are a common cause of morbidity and mortality in children (25). Infections can be of viral, 
bacterial, fungal, or parasitic origin and often result in symptoms such as fever, upper respiratory 
tract symptoms, rash, and fatigue. Respiratory viral infections are one of the most common causes of 
disease in younger children, causing mild symptoms to severe or even lethal conditions in children, 
especially those <1 year of age. Several different laboratory methods for microbiological agent 
detection, all with different sensitivity and specificity, can be used.  
 
1.2.1 Viral infections 
Viruses are intracellular infectious agents dependent on the host cell’s machinery to infect and spread. 
A virus consists of a small genome, either DNA or RNA, packed in a capsule of proteins called a 
capsid (12). For some viruses, this capsid is covered by a lipid layer membrane, and the virus is then 
called an enveloped virus. In general, an enveloped virus is more sensitive to external factors such as 
temperature, alcohol, pH, and dehydration than a non-enveloped virus. Viral infection can either be 
acute and cleared by the immune system (e.g., respiratory viruses, gastrointestinal viruses, measles) or 
incorporated in the host cell leading to persistent or latent infection (e.g., human immunodeficiency  
 
Figure 2: The NOPHO ALL-2008 protocol (reprinted with permission)   
 
Abbreviations: ALL, acute lymphoblastic leukemia; ANC, absolute neutrophil count; BM, bone marrow; CNS, central 
nervous system; d, day; HDM, high-dose methotrexate; HR, high risk; I, induction; IR, intermediate risk; 6-MP, 6-
mercaptopurine; MRD, minimal residual disease; MTX, methotrexate; NOPHO, Nordic Society for Paediatric Hematology 
and Oncology; PEG, Polyethylene glycol conjugated; R, Randomization; SCT, stem cell transplantation; SR, standard risk; 
T, Thrombocytes; TIT, triple intrathecal therapy; VCR, Vincristine.   
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virus (HIV), herpes virus, hepatitis B or C). Only a few drugs have been developed for the treatment 
of viral infections. The main difficulties in developing antiviral drugs arise because viral replication 
usually occurs before symptom onset, and therefore, the use of antivirals must be administered before 
or at least within a few days after symptom debut. Viral infections can range from both mild and 
transient infections to severe and persistent infection depending on both host factors (e.g., 
susceptibility) and virus type (12). Respiratory viral infections are one of the most common causes of 
morbidity in the population, especially in children, and these viruses are a main focus in this thesis 
(26).    
 
1.2.1.1 Respiratory viral infections  
Respiratory viruses can cause both upper and lower respiratory tract infections with symptoms such as 
cough, nasal congestion, runny nose, sore throat, muscle ache, fatigue, and fever (Table 1). The 
infections can vary from mild with minor symptoms to severe and even fatal with excessive 
symptoms, especially in younger children (25). To date, by using polymerase chain reaction (PCR), 15 
of the most common respiratory viruses are part of the standard analyses performed in many of the 
Swedish microbiological laboratories: adenovirus (HAdV), bocavirus (HBoV), coronaviruses (HCoV) 
NL63/OC43/229E/HKU1, enterovirus (EV), influenza virus A and B, metapneumovirus (HMPV), 
parainfluenza viruses (PIV) 1-3, respiratory syncytial virus (RSV), and rhinovirus (RV) (27) (Table 
1). In addition, the newly emerging HCoV, Severe Acute Respiratory Syndrome (SARS) CoV-2 is 
also analyzed using PCR in the Swedish laboratories. RV is the most frequently detected virus in 
immunocompetent children with acute upper respiratory illness, followed by HBoV and PIV (28-30). 
The most common respiratory findings identified in children with lower respiratory tract illness is 
RSV, RV influenza virus, and HMPV (31, 32). However, the clinical interpretation of PCR positivity 
for certain respiratory viruses is still challenging, as some of the respiratory viruses have been reported 
to be found frequently in asymptomatic subjects and persist weeks after the acute infection. In 
asymptomatic children, RV is the most frequently detected virus, with a detection rate of ~30%, 
followed by HCoV, HBoV, and HAdV at ~6–13% (28, 29, 31-34), in contrast to some respiratory 
viruses that are rarely detected in asymptomatic children, such as influenza, RSV, and HMPV (29, 31, 
32) (Table 1). Due to the vast number of different subtypes of respiratory viruses (i.e., RV is abundant 
in over 100 subtypes) and frequently developed mutations in viral genomes, individuals can be 
repeatedly affected by respiratory viral infections. 
 
1.2.2 Bacterial infections 
Bacteria are prokaryotic microorganisms and are larger both in size and genome compared to viruses 
(12). Most bacteria consist of a circular chromosome with double-stranded DNA packed into a 
nucleoid. Bacteria can also carry extrachromosomal DNA, called plasmids, which contain genes 
important for virulence factors or antibiotic resistance. Almost all bacteria have a cell wall consisting 
of a peptidoglycan layer and one or two phospholipid membranes. Gram staining is a technique used 
to distinguish and broadly classify bacteria based on the structure of the cell wall as either Gram-
positive (thick peptidoglycan layer, no outer membrane) or Gram-negative (thin peptidoglycan layer 
and an outer membrane). Specific structures are abundant in the membrane of the bacteria, such as 
lipopolysaccharide (LPS) (Gram-negative bacteria) and teichoic acid (Gram-positive bacteria).  
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Bacteria can display many different shapes, of which the most common are cocci (round), bacilli (rod-
shaped), and spirilla (spiral). Bacterial infections are usually rapidly cleared by the immune system, 
but can sometimes lead to host colonization (12). In contrast to antivirals, antibiotic treatment for 
bacteria is widely used, and many different drugs have been developed targeting specific bacteria. 
However, an increase in detected resistant bacteria (e.g., methicillin-resistant Staphylococcus aureus 
(MRSA) and vancomycin-resistant Enterococcus (VRE)) has become an issue due to extensive 
antibiotic use during the past decades; therefore antibiotic resistance is increasingly problematic (35, 
36). Bacteria can cause mild and local infections, as well as severe bacterial bloodstream infections 
(BSIs) that in some cases can be lethal. 
 
1.2.2.1 Bacterial bloodstream infections 
Bacteria can enter the blood in several different ways (e.g., through the respiratory or gastrointestinal 
tract, wounded skin, or through catheters). Presence of bacteria in the bloodstream, referred to as 
bacteremia, is a serious condition that may induce a massive inflammatory response. If the bacteremia 
leads to a systemic impact and organ dysfunction, a severe condition called sepsis has developed. 
Septic shock usually refers to a condition in which the patient with sepsis is not able to sustain an 
adequate blood pressure despite sufficient fluid supply, and this condition has a high mortality rate in 
pediatric patients (37). Many different types of bacteria, both Gram-positive and Gram-negative, can 
cause bacterial BSI. The most prevalent bacteria detected in blood cultures in immunocompetent 
children are S. aureus and E. coli (38).  
 
1.2.3 Overview of fungal infections 
Fungi exist all around us, from the ground to the air. They are microscopic spores and eukaryotic 
microbes with a cell wall. Most of them are harmless, although specific species can cause severe 
diseases in humans, particularly in immunosuppressed individuals. There are many types of different 
fungi, such as different Aspergillus species, dermatophytes, Candida species, Histoplasma, and 
Pneumocystis (12). Fungi spread through inhalation, orally, or through the skin. Fungi can colonize 
multiple sites such as the mouth, skin, and gastrointestinal tract, as well as cause invasive fungal 
disease (IFD) (39, 40). 
 
1.2.4 Laboratory methods for pathogen detection 
1.2.4.1 Methods for detecting viral infections 
Just one decade ago, the standard methods for detection of viral infections were antigen detection by 
immunofluorescence staining and viral culture (27). However, reagents (antibodies) for 
immunofluorescence staining were not available for all viruses, manual handling of the viral cultures 
was time-consuming, and the results were usually obtained after the acute infection had resolved. 
Today, these methods have almost entirely been replaced by molecular-based methods such as PCR, a 
widely used method for detecting many viral infections (e.g., respiratory, blood, and gastrointestinal). 
Thanks to its rapid response and high sensitivity, PCR is an important contribution in the 
microbiologic diagnostic work-up in clinical practice (12, 27, 41). As the method is based on 
amplification of nucleic acids, it can detect even small amounts of specific RNA or DNA fragments 
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(41). The most commonly used PCR technique today is the real-time PCR, a quantitative method with 
the ability to indirectly measure the amount of a specific microorganism in a given sample (12). In the 
real-time PCR analysis, a cycle threshold (Ct) value is calculated, and the lower the Ct value, the 
higher the viral load is in the original sample (41). One major limitation that remains with this method 
is the inability to differentiate viable pathogens from remnants of nucleic acid fragments from 
pathogens (27, 41). Therefore, due to viral remnants or asymptomatic infections, PCR findings can 
sometimes be difficult to interpret in a clinical setting. In addition, PCR can only identify pre-
specified sequences of pathogens and thus it is sensitive to mutations in the primer or probe binding 
regions of the pathogens. Therefore, viral culture can still have an important role in detecting novel 
viruses that are not discovered with PCR. Another method for detection of viral infection is serology, 
a method based on detecting antibodies as a response to a pathogen, such as through enzyme-linked 
immunosorbent assays (ELISAs) (12). Levels of acute antibodies, such as immunoglobulin (Ig) M, 
rise and can be detected in serum a few days from infection onset, and long-term antibodies called IgG 
rise after a few weeks. The slow response hampers result interpretation in the acute phase of infection; 
therefore, serology is commonly used to determine immunity. Newer methods for detection, such as 
next-generation sequencing (NGS) (e.g., RNA and DNA sequencing) have not yet been implemented 
in the clinical diagnostics of viral infection and are currently mainly used for research purposes. 
 
1.2.4.2 Methods for detecting bacterial infections  
Culturing (blood or local) is an older but still commonly used method in microbiology, mainly used 
for bacteria and fungi. By using cultures, antimicrobial resistance can be determined, leading to more 
individualized antibiotic treatment. Cultures can be collected either from a normally sterile 
compartment, such as blood or cerebrospinal fluid, or from compartments that might be colonized 
with bacteria. If a sample is taken from a possibly colonized compartment, it is important to separate 
those bacteria included in the normal flora from pathogenic bacteria. Culturing has several limitations. 
First, it usually takes 12–24 hours for the bacteria to grow (sometimes even longer). Second, some 
bacteria grow poorly or not at all in culture medium and therefore the ability to select therapy could be 
limited (42). Importantly, it is known that blood culture sensitivity is especially low in pediatric 
patients, often due to inadequate blood volume (43, 44). Other methods for bacteria detection are PCR 
(atypical bacteria, e.g., mycoplasma and chlamydia) and serology (atypical bacteria). A few NGS 
methods, such as the 16 S sequencing method is used in the clinic. The method can detect bacteria at 
species levels and is of importance for bacteria that are not identified through culture (e.g. slow 
growing or uncultivable bacteria), bacterial infections at sterile compartments or to detect rare bacteria 
(45). However, many of the NGS methods are still used mainly for research purposes.  
 
1.2.4.3 Methods for detecting fungal infections  
Fungal infections can be diagnosed through culturing of blood or local compartments, microscopy, 
PCR, and in some cases, through radiology (e.g., computed tomography scan) (46, 47). However, the 
diagnostic tools for fungal infections are still limited, as both the molecular diagnostic methods and 
cultures have limitations, such as low sensitivity (48-50).  
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1.3 INFECTIONS ASSOCIATED WITH FEBRILE NEUROPENIA IN CHILDREN 
TREATED FOR CANCER 
Due to the side effects of chemotherapy, mainly neutropenia and disrupted epithelial barriers, children 
treated for cancer are at increased risk of infections (51). Sometimes fever is the only symptom of a 
severe infection. Fever coinciding with neutropenia is a condition called febrile neutropenia. The 
most common reason of febrile neutropenia is thought to be infection. Viral infections, especially 
respiratory viral infections, are the most commonly detected infections during episodes of febrile 
neutropenia (52). Bacterial BSIs and IFDs are the most common causes of infection-related deaths in 
children with cancer (53-55). Infection-related deaths account for approximately 1–3% of the deaths 
during cancer treatment, and the relatively low number is probably due to more effective management 
of these patients (54-56). On the other hand, of all the deaths during cancer treatment, infections can 
account for as much as 70% (54). In addition, morbidity due to infections is still high with infection-
related complications, delayed chemotherapy treatments, and hospitalization as consequences (57). 
 
1.3.1 Febrile neutropenia 
Febrile neutropenia is defined as a neutrophil count ≤0.5 × 109/L on one occasion or ≤1.0 × 109/L with 
a decrease to ≤0.5 × 109/L over a subsequent 48-hour period together with fever, defined as a 
temperature ≥38.0°C, on two occasions 60 minutes apart or ≥38.5°C on one occasion (58). Febrile 
neutropenia is a dreaded complication during chemotherapy treatment because an untreated infection, 
mainly bacterial or fungal, can worsen rapidly and progress to fatal sepsis. Therefore, when children 
treated for cancer contract a fever, they need immediate medical care. At admission, a thorough 
clinical examination should be performed, laboratory samples taken, and broad-spectrum antibiotics 
started within one hour from entering the emergency room (59). To distinguish between children with 
low or high risk of severe infection several predictive rules have been proposed. However, none of 
these rules has yet been fully validated (60-62). Further, not all episodes of febrile neutropenia are 
infection-related; the fever can also be caused by the cancer itself, transfusion of blood products, or 
treatment related (chemotherapy drugs). In many cases of febrile neutropenia, no underlying cause of 
the fever can be identified, and the fever is defined as fever of unknown origin (FOU) (63). Infection-
related causes have been the main focus during this thesis and will therefore be discussed further. 
Febrile neutropenia episodes are more abundant at the beginning of the treatment (e.g., induction and 
consolidation phases during ALL treatment) when the intensity of the chemotherapy treatment is 
highest and the children are not yet in remission of the disease (55, 56, 64). Children with febrile 
neutropenia are usually treated with broad-spectrum antibiotics for a median of 4–10 days and 
admitted to the hospital for a median of 4–8 days (52, 65-69). The long hospitalization has negative 
social effects for the child and their family, and the use of broad-spectrum antibiotics increases the 
risk of subsequent infection with antibiotic-resistant bacteria and fungi (70-72). 
 
1.3.2 Viral infections during episodes of febrile neutropenia 
Only during the last few years have viral infections been recognized when investigating febrile causes 
in children with cancer. In HSCT children, viral infections are associated with a high morbidity and 
mortality, whereas viruses are rarely reported as cause of infection-related deaths in children treated 
for cancer (54, 73-75). However, respiratory viral infections are still often detected during episodes of  
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febrile neutropenia in children treated for cancer and thus are suspected to cause high morbidity in this 
patient cohort. Other viruses, such as gastrointestinal viruses, different herpesviruses, and parvovirus 
B19 (B19V), are also detected.  
 
1.3.2.1 Respiratory viral infections during episodes of febrile neutropenia 
The role of respiratory viral infections in children with cancer has been subject to debate. One decade 
ago, viral infections were rarely reported during episodes of febrile neutropenia (63, 76). However, 
over the last few years, this has shifted, not only due to the introduction of PCR for detection of 
respiratory viruses, but also due to more frequent testing for respiratory viruses during episodes of 
febrile neutropenia. Currently, respiratory viruses are reported in 44–52% of all febrile neutropenia 
episodes (52, 65, 66), and the number is even higher (>75%) in patients with acute respiratory 
symptoms at the time of the febrile neutropenia episode (67). RV is the most frequently detected virus, 
followed by RSV and HCoV (52, 65-67, 77). Respiratory viruses are detected throughout the entire 
treatment period, notably even during the maintenance phase of ALL treatment (56). Respiratory 
viruses have in a few cases been reported as causes of death during pediatric cancer treatment, mainly 
RSV, influenza, HAdV, and one of the latest reports with HCoV OC43 (54, 78). In addition, 
secondary bacterial infection after viral infection have been reported with a few fatal cases (67). 
Nevertheless, in the majority of episodes with a positive respiratory viral finding, symptoms are mild 
and the outcomes often favorable (52, 65, 77). The interpretation of respiratory viruses, especially of 
RV, in terms of clinical significance remains challenging because these viruses have been detected in 
immunocompetent asymptomatic children and in children weeks after an infection (28, 29, 33, 34, 79) 
(Table 1, p. 7), and a simultaneous bacterial infection is difficult to rule out. 
 
1.3.2.2 Other viral infections during episodes of febrile neutropenia  
Gastrointestinal viruses (e.g., norovirus, HAdV, and rotavirus) are also commonly detected viruses in 
children with cancer (56, 80). Some of these viruses have been detected even months after the acute 
infection, which hampers the interpretation of these viral findings in the clinic (81, 82). Herpesviruses, 
such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpes virus 6 (HHV6), and 
varicella, are relatively rare during episodes of febrile neutropenia in children treated for cancer, 
reported in ~1–10 % of the episodes, where HHV6 and CMV are more commonly and rarely detected, 
respectively (52, 76, 83). These viruses can either cause primary infection or be reactivated in 
immunosuppressed children, which in both cases can cause severe disease (84). B19V is another virus 
that can be detected during cancer treatment, detected in ~2% of febrile neutropenia episodes and 
~15% during the entire course of ALL treatment (52, 85). B19V can be a cause of cytopenia during 
cancer treatment, leading to decreased dose intensity and complications during treatment (85). 
 
1.3.3 Bacterial infections during episodes of febrile neutropenia 
Bacterial infections in children treated for cancer have been well investigated, mainly due to the fact 
that bacterial BSI is a dreaded complication during cancer treatment, as an untreated infection can 
rapidly lead to sepsis development in this patient cohort. Local bacterial infections that are commonly 
reported during cancer treatment in children are E. coli urinary tract infection, Clostridium difficile 
gastrointestinal infection, and skin infections caused by Streptococcus species and S. aureus (57). 
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1.3.3.1 Bacterial bloodstream infections during episodes of febrile neutropenia 
Bacterial BSIs have been a main focus area within the research field of febrile neutropenia (86, 87). 
However, although a bacterial agent is only identified in approximately 10–30% of febrile neutropenia 
episodes, almost 100% are treated with broad-spectrum antibiotics for several days (52, 63, 65, 76, 87, 
88). The most common bacteria detected in blood during cancer treatment in children are Gram-
positive bacteria (coagulase-negative staphylococci, viridans streptococci, and S. aureus) (56, 63, 76, 
87, 88). Gram-negative bacteria are also detected, such as E. coli and Pseudomonas aeruginosa, but 
these are less common (56, 63, 76, 87, 88). However, because blood cultures have a limited sensitivity 
to detect bacterial BSIs in children, it is difficult to exclude a pathogen simply by a negative blood 
culture; other plausible methods for bacterial pathogen detection are thus needed (43, 87, 89).  
 
1.3.4 Fungal infections during episodes of febrile neutropenia 
Fungal infections mainly affect immunosuppressed patients. It is common with colonization of fungi 
during cancer treatment, not causing any active disease (90). However, if the fungi is spread into the 
bloodstream it can lead to IFD, causing severe disease in immunosuppressed patients (86).  
 
1.3.4.1 Invasive fungal disease during episodes of febrile neutropenia  
IFD can lead to disseminated disease, a severe condition in which multiple micro-abscesses are 
formed in otherwise sterile compartments in the body, such as the lungs, liver, spleen, brain, and 
kidneys (91). Diagnosis of IFD is complicated and hampered by the scattered clinical picture of fungal 
disease, low sensitivity of blood cultures, and difficulty in distinguishing fungal colonization from 
invasive disease (39, 92). Therefore, specific criteria for the diagnostics of invasive fungal infection 
have been developed by the European Organization for Research and Treatment of Cancer (EORTC) 
and National Institute of Allergy and Infectious Diseases Mycoses Study Group (MSG) (93). Through 
the EORTC/MSG criteria involving microbiological testing, risk factors, and radiology, fungal 
infections are categorized as “proven,” “probable,” and “possible”(93). The most commonly identified 
invasive fungal infections in children with cancer are Candida, Aspergillus, and Pneumocystis jiroveci 
(39, 94, 95). IFD is a prominent cause of infection-related deaths in pediatric patients treated for 
cancer (53-56, 86). Therefore, the start of antifungal treatment is crucial and should (if not already 
prophylactically given) be given to children treated for cancer on wide indications where continuation 
of fever despite antibiotic treatment and IFD is suspected (i.e., should not be delayed by insufficient 
diagnostics) (59).  
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1.4 SUSCEPTIBILITY TO NEUTROPENIA AND FEBRILE NEUTROPENIA IN 
CHILDREN TREATED FOR ALL 
There is considerable variety in the frequency and severity of side effects, such as neutropenia and 
febrile neutropenia, in children treated for cancer, implying that specific genetic variants might affect 
susceptibility to these events. Pharmacogenetics refers to the study of the individual variability in drug 
response due to genetic variations or heredity (96). Therefore, pharmacogenes have been suggested 
to impact the susceptibility to neutropenia and febrile neutropenia during pediatric cancer 
treatment. Moreover, proteins important in the immune system have also been suggested to influence 
the susceptibility to episodes of febrile neutropenia and microbiological defined infections (MDI) 
during these episodes. Considering that these events increase morbidity and delay further treatment, 
there is a need to identify risk factors for developing these conditions (63). 
 
1.4.1 Genetic variants 
In the next section, different genetic variants, also called sequence variants, in specific genes will be 
discussed. To facilitate further reading, adequate basic genetic principles and terminology are 
introduced in this section. In general, the term “polymorphism” refers to a sequence variant in the 
DNA chain that occurs in >1 % of the population, and the term “mutation” if it occurs in <1%. The 
terms “genetic variant” or “sequence variant” is used in this thesis to describe both polymorphisms 
and mutations (97). 
   The genome refers to an individual’s complete genetic material, and the human genome is stored in 
23 pairs of chromosomes. A chromosome is a long chain of DNA, which consists of two strands of 
nucleotides bases (A, T, C, and G) (98, 99). The coding regions of a DNA chain are called exons and 
non-coding regions introns. Through a process called transcription, the DNA functions as a template 
to yield complementary RNA. The introns of the RNA chain are then spliced, forming messenger 
RNA (mRNA). The mRNA codes for amino acids, and these are formed together in a specific order to 
produce a protein in a process called translation. The transcriptome is the term for RNA expressed 
by an organism or refers to the RNA transcripts produced by a particular cell. The transcriptome is 
actively changing, depending on which genes that are activated at a given point in time; hence, it can 
be considered a more precise measure of the cell’s current activity compared to the measurement of 
proteins, called proteomics. However, not all RNA transcripts are translated to proteins, and 
therefore, both the transcriptomics and proteomics are needed to better understand the functionality. 
   A gene is a sequence of DNA that can encode a protein and thereby determines a specific trait. The 
human genome is estimated to encode ~20,000–25,000 genes (100). Each gene has a specific location 
on a chromosome called a locus and exists in two copies, one inherited from each parent. These two 
copies are not necessarily the same, and there may be small differences in the genes. The different 
copies are called alleles. An allele is a specific form of the gene, located at the same site on the two 
paired chromosomes, one inherited from each parent. Together, the two alleles are called a genotype. 
A genotype can either be heterozygous or homozygous, meaning it either consists of two different 
alleles or two of the same alleles, respectively. Further, the homozygous alleles can be either “wild 
type”, meaning that it consists of the two most commonly occurring alleles in a population, or 
“mutant/polymorphic”, meaning it consists of the two less occurring alleles. An allele is responsible 
for variations in which a given trait, i.e., phenotype, can be expressed. In addition, alleles can be 
dominant, act in a co-dominant fashion, or be recessive (97).   
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   Several different genetic variants exist, with the most common being the single nucleotide 
polymorphisms (SNPs), meaning a substitution of a single nucleotide at a specific position in the 
genome that constitutes a sequence variant in the DNA chain (97, 101). Therefore, the different 
sequence variants give rise to differences in the alleles. SNPs are common in the human genome, and 
depending on the location of the SNP, it can either have dramatic consequences for the protein or not 
affect the protein at all. Within a cohort, some sequence variants are more common than others and 
therefore are called the “major allele,” whereas the less common variant is called the “minor allele” 
(97). The allele frequency is the relative frequency of an allele at a specific position in a defined 
population, expressed as either a fraction or percentage (97). The allele frequency is not the same as 
genotype frequency. However, it can be calculated if the genotype frequency is known. SNPs are 
identified in different frequencies in populations, and therefore, the “major allele” in one population 
may be the “minor allele” in another population. Other genetic variants can be tandem repeat 
polymorphisms. Tandem repeats occur in DNA when nucleotides are repeated directly adjacent to 
each other in a specific number of base pairs. Tandem repeats can then be abundant in variable copies 
of the repeats (e.g., two or three copies) and therefore affect the phenotype.  
   Genotyping is a method for SNP detection. Several different genotyping methods can detect 
novel/unknown SNPs, as well as methods whereby already known SNPs can be detected. Genome or 
exome sequencing can detect novel/unknown SNPs throughout the entire genome, whereas methods 
such as pyrosequencing or PCR-based methods can detect specific and already known SNPs. Gel 
electrophoresis can be used for detecting tandem repeats (101, 102). Some of these specific methods 
will be described in more detail in the method section.   
 
1.4.2 Sequence variants in important pharmacogenes  
Common side effects of chemotherapy (as described above) are neutropenia and febrile neutropenia. 
Despite identical treatment protocols for ALL, some patients suffer from more frequent episodes of 
neutropenia and febrile neutropenia, suggesting a genetic predisposition in genes crucial for drug 
metabolism. Thiopurines, mainly 6-MP, are drugs commonly used for the treatment of ALL, and a 
common side effect is cytotoxicity of the host’s blood cells. Thiopurine methyltransferase (TPMT) is 
an enzyme with a documented ability to affect thiopurine metabolism, and sequence variants in this 
gene have been identified to increase the risk of side effects during ALL treatment (103-105). Dose 
reduction for TPMT-deficient children have already been implemented in the NOPHO ALL 2000 and 
2008 treatment protocols. However, despite these implementations, some children still experience 
various numbers and degrees of side effects, and other enzymes in thiopurine metabolism, such as 
inosine triphosphate pyrophosphatase (ITPA) and Nudix hydrolase 15 (NUDT15), have also been 
suggested to affect the cytotoxic effect of thiopurine through altered drug metabolism.  
 
1.4.2.1 6-MP 
The thiopurine drugs, such as 6-thioguanine, azathioprine, and 6-MP, are purine analogs that can be 
incorporated in RNA and DNA as “fake” monomers. The main thiopurine used during ALL treatment 
is 6-MP, administered almost every day of the 2.5 years of treatment and is therefore discussed in 
more detail in this thesis. 6-MP was discovered in the 1950s and was almost immediately introduced 
as a treatment for ALL (106). However, thiopurines are also incorporated in normal cells (mainly 
rapidly dividing cells such as blood cells), leading to side effects. Furthermore, 6-MP is a pro-drug 
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that needs to be metabolized to exert cytotoxicity. The metabolism of 6-MP is a complex procedure 
that depends on several different enzymatic reactions (Figure 3) (107-112). The final active products 
produced are: (i) deoxy thioguanosine triphosphate (TdGTP) and thioguanosine triphosphate (TGTP), 
which can be incorporated in DNA or RNA, respectively, as purine antagonists to interfere with 
replication and induce apoptosis of the cell, (ii) TGTP that binds to RAC1, which induces apoptosis of 
activated T cells, and (iii) formation of methyl-thioinosine monophosphate (meTIMP), which inhibits 
the de novo synthesis of purine nucleotides (110, 112-115). Tioguanine nucleotides (TGNs) 
generically describes all the thiopurine drug metabolites (TGMPs, TGDPs, TGTP, and the deoxy 
variants). Enzymes convert 6-MP to its active product or can degrade 6-MP to a non-active 
metabolite, such as TPMT, NUDT15, and ITPA (106, 107, 110, 112, 116, 117). Hence, these enzymes 
may therefore regulate the cytotoxic effect of 6-MP (105, 107, 118-129).   
 
 
Figure 3: 6-MP metabolism. 6-MP can exert its cytotoxic affect through three different pathways: (i) by 
affecting RNA and DNA, leading to apoptosis, (ii) RAC1 inhibition leading to inactivation of T cells, and 
(iii) formation of meTIMP, which inhibits de novo purine synthesis. 
 
Abbreviations: ITPA, inosine triphosphate pyrophosphatase; MeMP, methylated mercaptopurine; MeTIMP, 
methylated thioinosine monophosphate; 6-MP, 6-mercaptopurine; NUDT15, Nudix hydrolase 15; PPAT, 
phosphoribosyl pyrophosphate amidotransferase; RAC1, Rac family small GTPase 1; TdGDP, deoxy thioguanosine 
diphosphate; TdGMP, deoxy thioguanosine monophosphate; TdGTP, deoxy thioguanosine triphosphate; TGDP, 
thioguanosine diphosphate; TGMP, thioguanosine monophosphate; TGTP, thioguanosine triphosphate; TIMP, 
thioinosine monophosphate; TITP, thioinosine triphosphate; TPMT, thiopurine S-methyltransferase; TUA, thiouric 
acid.      
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1.4.2.2 TPMT 
The enzyme TPMT has the ability to inactivate 6-MP by metabolizing it to non-toxic compounds 
through methylation of the drug to the inactive product: methylated mercaptopurine (meMP) (Figure 
3) (130). However, TPMT can also produce an active product (meTIMP) that is toxic for the cell 
because it inhibits de novo purine synthesis in the cell (Figure 3) (131, 132). There are many known 
sequence variants in the TPMT gene, and the most frequently studied alleles are TPMT*2 (238G>C), 
TPMT*3A (460G>A and 719A>G), TPMT*3C (719A>G), and the more rare allele TPMT*3B 
(460G>A) (105, 133-135). TPMT*2, *3A, and *3C are together responsible for ~95% of variant 
alleles (105, 135-137). Sequence variants in the TPMT gene are identified in ~2–10%, with lower and 
higher frequencies in Asian and Caucasian populations, respectively (105, 138). A sequence variant in 
the TPMT gene results in reduced levels of TPMT enzyme activity, which in turn accumulates the end 
products of 6-MP (TGPT and TdGTP) and the risk of cytotoxic events increases during thiopurine 
treatment (103, 135, 139-144).  
   TPMT has been well-investigated in children treated for ALL. TPMT-deficient children have an 
increased susceptibility to thiopurine-induced toxicity, such as myelosuppression (Table 3, p. 40) 
(103, 105). Therefore, implementations were made in the NOPHO ALL 2000 and 2008 protocols with 
dose reduction for children deficient in the TPMT gene (23, 24). Interestingly, studies have shown a 
correlation with a higher probability for relapse when TGN levels are low (hence in individuals with 
high TPMT activity) and a decreased risk of relapse in TPMT-deficient children (103, 145-147). 
Follow-up studies after the implementation of dose adjustments have also indicated an increased risk 
of relapse in TPMT-deficient patients (148).  
 
1.4.2.3 ITPA 
The ITPA enzyme has the ability to hydrolyze thioinosine triphosphate (TITP) to thioinosine 
monophosphate (TIMP) nucleotides where TIMP is an important intermediate in the purine synthesis 
(Figure 3) (149). Accumulation of TITP is thought to be toxic for the cell, and ITPA protects the cell 
from accumulating this product (150). Two different sequence variants have been more frequently 
investigated and associated with enzyme deficiency: ITPA rs7270101 (IVS2+21A>C) and ITPA 
rs1127354 (94 C>A) (150). Sequence variants in ITPA are identified in 5–19% of the population and 
are more common in Asian compared to Caucasian populations (151). Sequence variants in ITPA 
rs1127354 and rs7270101 have shown decreased ITPA activity and therefore ITPA deficiency may 
result in the accumulation of toxic TITP (107, 118, 150). No effect on TGNs levels have been 
identified in ITPA deficiency (107, 118, 152).  
   In children treated for ALL, ITPA deficiency has in some studies been associated with side effects 
during 6-MP treatment, whereas other studies have failed to show any significant association between 
ITPA sequence variants and side effects (Table 3, p. 40) (107, 118, 119, 123, 125, 152-155). 
Therefore, the clinical significance of ITPA deficiency is still debated, and the contradictory results 
reflect the complex nature of thiopurine metabolism. No dose adjustment for ITPA-deficient patients 
has been implemented in the NOPHO ALL protocols.  
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1.4.2.4 NUDT15 
The NUDT15 enzyme is thought to convert the active thiopurine metabolites TGTP and TdGTP 
through dephosphorylation to thioguanosine monophosphate (TGMT) and deoxy thioguanosine 
monophosphate (TdGMP) (Figure 3) (156, 157). Therefore, NUDT15 prevents cytotoxic TGTP and 
TdGTP from being incorporated into DNA or RNA (128, 157, 158). One sequence variant in the 
NUDT15 gene, NUDT15 rs116855232 (c.415C>T), is the most commonly detected and investigated 
variant (128, 157). NUDT15 sequence variants are identified in ~0.2–20 % of the population, with the 
highest and lowest numbers identified in Asian and European populations, respectively (128, 157). 
Sequence variants in NUDT15 directly result in excessive levels of thiopurine active metabolites, such 
as TGTP and TdGTP (but not the total TGN) (120, 157, 159). Therefore, NUDT15 deficiency may 
lead to an increased risk of thiopurine toxicity (157, 159). 
   Investigating sequence variants in the gene coding for NUDT15 in children with ALL has had an 
emerging role in recent years. The studies conducted have consequently identified NUDT15 as a risk 
factor for side effects such as myelosuppression and showed the need of 6-MP dose reduction in 
deficient patients (Table 3, p. 40) (119, 125, 128, 160, 161). These studies indicate an important role 
of NUDT15 deficiency. NUDT15 was recently implemented in the treatment protocols for ALL 
(ALLTOGETHER) currently used in Sweden (162).   
 
1.4.3 The immune system 
Because genetic variants in important proteins of the immune system are investigated in this thesis, 
some basic immunology is briefly described in this section to facilitate further reading. Pathogens are 
present all around us, trying to invade our barriers. The immune system is a defense barrier against 
these pathogens, preventing us from constantly being infected by these microbes. In most cases, 
encountered microbes are eliminated before symptom onset, while sometimes the immune system 
fails to eliminate microbes, thus allowing an infection to be established. The immune system is usually 
divided into the innate and adaptive immune systems, with several overlapping cell types, as well as 
the complement system. In children treated for cancer, the regular immune response is weakened or 
missing due to the chemotherapy treatment and sometimes by the cancer itself.   
 
1.4.3.1 The innate immune system 
The innate immune system is the first line of defense against microbes and can recognize pathogens 
directly, react to host cells that have been damaged, and activate the adaptive immune system (163). 
The innate immune system consists of epithelia, functioning both as a barrier and a reservoir of 
immune proteins against infection, cells in the blood and peripheral tissues, and plasma proteins. 
Important cells in the innate immune system are phagocytes, which includes both neutrophils and 
monocytes that differentiate to macrophages or dendritic cells in tissue (Figure 1, p. 3). Another 
important cell type is the natural killer (NK) cell, which can recognize damaged or infected host cells 
and induce apoptosis. The cells of the innate immune system use different receptors, such as Toll-like 
receptors (TLRs), cytokine receptors, formyl methionine peptides, mannose receptors, and scavenger 
receptors to recognize microbes. When a pathogen attaches to these receptors, a cascade of events 
follow that ultimately lead to transcription of genes involved in the inflammatory response, during 
which inflammatory cytokines are produced, such as ILs (especially 1, 6, and 12), tumor necrosis 
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factor (TNF), chemokines, and interferon (IFN)-g. The cytokines then activate and mediate many of 
the reactions involved in innate immunity, such as inflammation, communication between leukocytes, 
and activation of the adaptive immune response (163). 
 
1.4.3.2 The complement system  
The complement system is an important part of the immune system that can enhance the role of 
phagocytes and antibodies (163). The complement system is activated in three different ways: 
alternative pathway (innate immune response), lectin pathway (innate immune response), and the 
classical pathway (adaptive immune response). The complement system can initiate a cascade of 
events in which the end product enables opsonization to facilitate phagocytosis, cytolysis of microbes 
by forming pores in the membrane, and stimulation of the inflammatory response from various 
leukocytes (163).  
 
1.4.3.3 The adaptive immune system 
The adaptive immune system is subsequently activated and constitutes a more specific defense against 
pathogens (163). The adaptive immune system consists of lymphocytes: B cells (humoral immunity) 
and T cells (cell-mediated immunity) (Figure 1, p. 3), which are activated after microbes have passed 
through the epithelial barrier and reached the lymph nodes. Although, during recent years the 
distinctions between the innate and adaptive system are not mutually exclusive, since some of the cells 
have been identified to affect both systems (e.g. NK memory cells) (164, 165). Lymphocytes express 
receptors that recognize molecules called antigens that are produced and expressed on microbes (163). 
When an antigen binds to the naive B cell, the cell differentiates into an effector cell called a plasma 
cell, which can produce antibodies that can neutralize and eliminate microbes. Plasma cells can be 
long-lived and produce antibodies in the absence of antigen, therefore providing a level of protection 
if the antigen is re-encountered. Some B cells also differentiate into memory B cells, which do not 
secrete antibodies but respond rapidly if the antigen is re-introduced. T cells can be grouped as CD4+ 
T cells (T helper cells and regulatory T cells) or CD8+ T cells (cytotoxic T cells). T helper cells and 
cytotoxic T cells are effector cells. T helper cells produce cytokines that activate B cells and 
macrophages. Cytotoxic T cells eliminate host cells infected with intracellular microbes. A fraction of 
the T cells become memory T cells, which can be more long-lived and be rapidly activated if the 
antigen is re-introduced (163).  
 
1.4.4 Sequence variants in important proteins in the innate immune system  
Sequence variants in genes important in the immune system are common, and some of these variants 
may affect infection susceptibility and side effects to different extents. Mannose-binding lectin 
(MBL), TLR4, and IL-1 receptor antagonist (IL-1Ra) are three different proteins important in the 
immune system that have been identified as potential risk factors for episodes of febrile neutropenia 
and associated MDI.  
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1.4.4.1 MBL  
MBL is a plasma protein produced in the liver that is an important protein for the innate immune 
system, as it activates the lectin pathway of the complement system (163). The MBL2 gene codes for 
the MBL protein (166). Three sequence variants in the MBL2 gene located in an exon are commonly 
detected and investigated: codon 52 (allele D), codon 54 (allele B), and codon 57 (allele C) (167-169). 
In addition, three sequence variants in the promotor region of the MBL2 gene have also been shown to 
affect the protein levels to different extents: H/L, Y/X, and P/Q (170, 171). However, a strong linkage 
disequilibrium between the sequence variants in the promotor and the exon regions has been observed 
(170). MBL sequence variants are fairly common with a detection rate of 20–50%, whereas variant 
and frequencies vary within different populations (168, 169, 172). Sequence variants in the MBL 
gene, mainly the exon regions and one of the promotor regions, have been correlated with lower 
serum levels of MBL protein (170, 171, 173, 174).  
   In some studies of immunocompetent pediatric and adult cohorts, sequence variants in the MBL 
gene have been correlated with an increased risk of infections, such as higher risk for systemic 
inflammatory response, sepsis, and respiratory infections (173-178). However, studies have also 
shown discrepant results in the role of MBL during infectious episodes (179, 180). Several studies 
have investigated sequence variants in the MBL gene in children undergoing treatment for cancer 
(Table 4, p. 44). Similar to the immunocompetent patient group, results have been contradictory when 
investigating the association between sequence variants in the MBL gene and episodes of febrile 
neutropenia and MDI (181-186).  
 
1.4.4.2 TLR4 
TLRs are receptors used by the innate immune system to recognize molecules presented on different 
pathogens (163). These receptors are present both extra- and intracellularly and in many different cell 
types, such as phagocytes, dendritic cells, lymphocytes, and endothelial cells. TLRs are specific to 
different molecules shared by classes of microbes, such as LPS presented on Gram-negative bacteria 
and single- or double-stranded RNA of viruses. Immune cells are activated when the specific ligand 
on the pathogen attach to the corresponding TLR. When a pathogen is discovered by a TLR, immune 
cells are activated, leading to transcription of genes involved in the inflammatory response (Figure 4) 
(163). TLR4 is present on the cell surface and is one of the most important TLRs for the recognition 
of LPS presented on Gram-negative bacteria. Several sequence variants in the TLR4 gene are known, 
with rs4986790 (Asp299Gly) and rs4986791 (Thr399Ile) more commonly studied (187). The 
frequency of sequence variants in the TLR4 gene (for rs4986790 and rs4986791) varies from 0–18% 
and differs within populations (188). It has been reported that sequence variants in the TLR4 gene 
may alter the extracellular structure of the receptor, resulting in conformational changes of the binding 
site that may affect the binding of pathogen ligands such as LPS (189-191). Another possibility is that 
TLR4 inhibits neutrophil apoptosis, wherefore dysfunctional TLR4 may lead to a shorter neutrophil 
lifespan (192-194). However, due to the complex nature of the TLR4 receptor and difficulties 
investigating the exact function, the phenotypes of different sequence variants in TLR4 are not fully 
understood.  
   Sequence variants in the TLR4 gene have been correlated with an increased risk of infection, such as 
an increased risk of Gram-negative BSI, RSV infection, and pulmonary aspergillosis (195-199). 
However, contradicting results of the role of sequence variants in rs4986790 and the risk for Gram-
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negative BSI have also been reported (200, 201). During the past decade, several other sequence 
variants in the gene coding TLR4 have been discovered, but because these are relatively recently 
discovered, they are not as well-investigated as rs4986790 and rs4986791. Some studies have 
investigated sequence variants in the TLR4 gene and the risk of febrile neutropenia and associated 
MDI in patients treated for cancer (181, 202) (Table 4, p. 44). The studies conducted in adults indicate 
increased risks of Gram-negative BSIs, sepsis, and pneumonia (181, 202). One study of a pediatric 
cohort treated for cancer showed an increased risk of developing chemotherapy-induced neutropenia 
in children deficient in the TLR4 gene (203). 
 
1.4.4.3 IL-1Ra 
ILs are secreted as a response to pathogens and play essential roles in both the activation and 
maturation of immune cells. ILs can have both pro- and anti-inflammatory properties. The IL-1 family 
is an important group of ILs, with IL-1α and IL-1β as the two most studied proteins. Both proteins 
have a strong pro-inflammatory effect and are secreted in response to pathogens. IL-1α and IL-1β 
have a natural antagonist called IL-1Ra that is produced in the same cells as IL-1α and IL-1β (204). 
IL-1Ra can also bind to the IL-1 receptor, but the binding does not alter downstream signaling (205, 
206). IL-1Ra therefore regulates the inflammatory response by competing with IL-1α and IL-1β for 
the binding site of the IL-1 receptor; consequently, it has an anti-inflammatory action. IL-1Ra is 
encoded by the IL1RN gene (207). There are four commonly studied sequence variants within intron 
2 of the IL1RN gene (IL1RN*2-5), which consists of tandem repeats of an 86-base pair (bp) sequence. 
The IL1RN*1-5 alleles correspond to 4, 2, 5, 3, and 6 copies of the 86-bp sequence, respectively, and 
four copies is the most common allele (102). The frequency of the IL1RN*2 allele is reported in 
~20% of the population, while the IL1RN*3 allele is more uncommon (~4%) (102). Presence of the 
IL1RN*2 allele has been associated with an increased production of serum IL-1Ra (208, 209). 
However, contradictory results have also been presented, showing that homozygosity for the 
IL1RN*2 allele led to a decrease in IL-1Ra production from cultured peripheral blood mononuclear 
cells, while no difference was seen in its plasma levels of healthy donors or sepsis patients (210). 
Sequence variants in the IL-1Ra gene have been associated with an increased susceptibility to sepsis 
and also more severe sepsis with a higher mortality in cohorts of otherwise healthy adults (210, 211).   
   Studies investigating IL-1Ra in children with cancer are limited. However, one described an 
increased risk of septic shock in children with the presence of an IL1RN*2 allele (212) (Table 4, p. 
44). Another study focusing on adults with acute leukemia found no correlation between sequence 
variants in the IL-1Ra gene and infection risk (181).  
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1.5 MICROBIOLOGICAL ACTIVATION OF THE IMMUNE SYSTEM 
When a pathogen penetrates the mucosal barriers and enters the host, the immune system is activated 
in different pathways, depending on the type of pathogen. The patterns can be specific for viruses 
and bacteria (but also overlapping) to eliminate the pathogen as effectively as possible. These 
pathogen specific innate immune signatures” have recently been highlighted as potential new 
methods for pathogen detection.  
 
1.5.1 General innate pathway as a response to pathogens  
The first step in innate immune activation is when a pathogen is recognized by a specific receptor, 
called a pattern recognition receptor (PRR). PRRs recognize molecules on either bacteria or viruses 
and can be localized on the cell surface, such as TLRs, or intracellularly, such as retinoic acid-
inducible gene I like receptors (RLRs) and Nucleotide-binding oligomerization domain (NOD)-like 
receptors (NLRs) (213-219) (Figure 4). Binding to TLRs and RLRs is important for the production of 
IFN (type I) and other cytokines, whereas NLRs are involved in regulating IL-1β (213, 220, 221) 
(Figure 4). The most common and well-described pathway is through TLR signaling, which the 
following described pathway focuses on. The binding of a pathogen to the receptors causes a cascade 
of intracellular signaling through different kinases (MYD88 or Toll/IL-1 receptor (TIR)-domain) 
resulting in the production of interferon-regulating factor (IRF) (mainly 3 and 7) and nuclear factor 
kappa-light-chain-enhancer of activated B-cells (NF-kB) (12, 213-219) (Figure 4). These factors can 
Figure 4: Viral and bacterial innate immune activation.  
 
Abbreviations: CRP, C-reactive protein; Ds, Double stranded; IFN, Interferon; IL, Interleukin; IRAK, Interleukin-1 
receptor-associated kinas 4; IRF, Interferon regulatory factors; JAK1, Janus Kinas 1; LPS, Lipopolysaccharide; 
Myd88,myeloid differentiation primary respons 88; NF-kB, Nuclear factor kappa-light-chain-enhancer of activated B cells; 
NLR, Nod-like receptor; OAS, Oligoadenylate synthetase ; PKR, Protein kinase R; RLR, Retinoic acid-inducible gene-I-like 
receptor; Ss, Single stranded; STAT, Signal transducer and activator of transcription; TLR, Toll-like receptor; TNF, Tumor 
necrosis factor; TRAF, TNF receptor associated factor; TRIF, TIR-domain-containing adapter-inducting interferon-β; 
Tyk2, Tyrosine kinas 2  
Pro-
IL-1B
Endosome
Nucleus 
Cytosol 
IFN (type I)Cytokines 
(e.g. IL-1, IL-6, TNF)
IRF7IRF3
IRF7
NF-kB NF-kB
NFkB IRF3
TLR5
Ds RNA
TLR9
TLR7
TLR3
TLR4TLR6/TLR2
TLR8
ss RNA
ss RNA
CPG
DNA
Virus
Bacteria
TLR1/TLR2
TIRAPTIRAP TIRAP TIRAP Tram
MYD88 TRIFMYD88 MYD88
TRAF3TRAF6
MYD88
VirusBacteria
Triacyl lipo-
peptides
LPS
Viral proteins
TRIF
MYD88
MYD88
MYD88
Diacyl lipo-
peptides
LTA
Flagellin
NLR RLR
JAK1
Tyk2
STAT1
STAT2
IRF9
IFN (type I)
IFN 
(type I)
STAT1
STAT2
IRF9
IRAK1
IRAK4
IKK
TBK1
PKR
OAS
Fever
CRP
Hematopoesis
Activating 
immune cellsApoptosis
Intracellular 
viral and 
bacterial 
structures
IL-1B
 22 
then enter the cell nucleus and induce the transcription of immune genes, thus stimulating the 
production of cytokines (e.g., IL-1, TNF, IL-6, and IFN type I) (Figure 4). IFN is an important 
cytokine, and high levels are produced during viral infection and also during bacterial infection, but to 
a lesser extent (222). IFN can induce intracellular signaling through Janus Kinas 1 (JAK1) and Signal 
transducer and activator of transcription (STAT) and inhibit protein synthesis (both viral and cellular), 
leading to cell death. Two important pathways of inhibiting protein synthesis are through activating 
protein kinase R (PKR) and oligoadenylate synthase (OAS) (Figure 4) (12, 223-225). The main focus 
of this chapter is the innate immune system; however, the adaptive immune system is essential to clear 
an infection and generate immunity. The pathways are very simplified, with the intention to briefly 
describe the complex system so both the direct immune genes and clusters of associated genes can be 
identified and associated with an active immune response. Different signaling pathways are activated 
through PRRs, and all can tune the intensity, duration, and quality of the signaling cascades, thus 
generating an innate immune response very specific for the pathogen they are sensing.  
 
1.5.2 Diagnosing pathogens through host innate immune signatures  
New methods have recently been developed focusing on the specific gene expression patterns of the 
innate immune system elicited by certain pathogens. RNA sequencing and microarrays can measure 
the amount of RNA (i.e., the transcriptome) expressed by an organism or a cell type (e.g., leukocytes) 
at a given point in time. As RNA is produced upon activation of specific genes, measurements of 
RNA serve as an indirect estimate of which genes are currently activated, giving specific gene-
expression profiles. Therefore, using gene-expression profiling during infectious episodes could in the 
future be a promising alternative approach to traditional diagnostic methods of infectious diseases.  
 
1.5.2.1 Gene-expression profiling 
Specific signatures or gene expression patterns have been studied and identified in both adult and 
pediatric immunocompetent cohorts during viral and bacterial infections (226-230). Zaas et al. (2009) 
used a cohort of adults inoculated with RV, RSV, and influenza virus and compared those developing 
symptoms and those who did not. The study was able to identify a blood mRNA expression profile 
that could classify symptomatic respiratory viral infections (226). The specific viral signature 
identified was compared to gene expression specific for bacterial infections, and the authors thereby 
confirmed that their signature was viral-infection-specific and could distinguish between patients with 
viral and bacterial infections, as well as healthy controls. In a follow-up study, Zaas et al. (2013) 
selected gene sets to classify respiratory viral infections by using reverse transcription-PCR (RT-PCR) 
and were able to identify influenza with a sensitivity of 89% and specificity of 94% (231). However, 
the standard dogma in pediatrics that “children are not little adults” is likely true also for the immune 
response, so it is important to also perform such studies in pediatric cohorts. Ramilo et al., Hu et al., 
and Herberg et al. were able to identify specific pathogen-response signatures for viral and bacterial 
infections in children (227, 229, 230). To our knowledge, no study has yet investigated these specific 
signatures in a cohort of immunosuppressed children. If similar signatures could be identified in 
immunosuppressed children, this information could be used to distinguish different microbiological 
findings and specifically assess children with FOU to investigate potentially undetected pathogens 
during febrile neutropenia episodes.    
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2 AIMS 
 
This thesis had two overall aims:  
(i) To increase the knowledge of the causative agents in episodes of febrile neutropenia in 
children treated for cancer, with the long-term goal of improving the interpretation of 
microbiological findings in a clinical setting during these episodes (papers I and IV). 
(ii)  To assess risk factors of neutropenia and febrile neutropenia during pediatric ALL treatment, 
with the long-term goal of developing a more individualized treatment strategy and risk 
stratification for these events (papers II and III).  
 
The more study specific aims were:  
Paper I  
• To investigate the role of respiratory viruses as causative agens during episodes of febrile 
neutropenia in children treated for cancer using a longitudinal study design with repated 
sampling in virus positive children.  
Paper II 
• To evaluate if sequence variants in genes encoding enzymes important in the 6-MP 
metabolism, such as TPMT, ITPA and NUDT15, increase the risk of neutropenia and febrile 
neutropenia during pediatric ALL treatment.  
• To determine if the end dose of 6-MP during pediatric ALL treatment is altered depending on 
the child’s specific TPMT, ITPA, and NUDT15 genotypes.  
Paper III 
• To retrospectivly define and characterize the etiology of febrile neutropenia episodes during 
the 2.5 years of treatment for pediatric ALL.  
• To investigate if sequence variants in genes coding for proteins important in the innate 
immune system, namly TLR4, MBL, and IL-1Ra, increase the risk of suffering febrile 
neutropenia episodes and associated MDI.  
Paper IV:  
• To investigate the feasiability of gene-expression profiling as a diagnostic tool during febrile 
neutropenia episodes in a cohort of children treated for cancer. 
• To improve the knowledge of respiratory viruses role as infectious pathogens’ during febrile 
neutropenia episodes by the assesment of their specific gene expression profiles. 
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3 STUDY DESIGNS 
3.1 STUDY POPULATION AND SAMPLING 
Two different cohorts were included in this thesis. The first was a prospective cohort of children 
presenting with febrile neutropenia from which samples for papers I and IV were collected. The 
second was a retrospective cohort in which children were identified using the NOPHO ALL registry 
and from whom samples had already been collected for papers II and III.  
 
3.1.1 Cohort I 
Papers I and IV: Children aged 0–18 years treated for cancer at Astrid Lindgren Children’s Hospital, 
Stockholm, Sweden between January 2013 and June 2014 were eligible for enrollment. All children 
who met the criteria for febrile neutropenia (≥38.5°C on one occasion or ≥38.0°C on two occasions at 
least 60 minutes apart, combined with an ANC of either ≤0.5 × 109/L on one occasion or ≤1.0 × 109/L 
with a decline to less than ≤0.5 × 109/L over a subsequent 48-hour period) were prospectively enrolled 
in the study. Children could be included multiple times if they had recurrent episodes of febrile 
neutropenia, and a total of 87 episodes in 54 patients were included. All included samples were 
collected within 72 hours from fever onset. Nasopharyngeal aspirates (NPAs) (papers I and IV) and 
blood samples (paper IV) were taken at time of enrollment, and follow-up samples were collected 
after 1–8 weeks (blood samples were collected from all children and NPAs from all virus positive 
children) (Figure 5). Blood cultures were collected as part of the clinical routine, and information 
about microbiological and biochemical results was collected from the medical records. For paper IV, 
all available samples from virus- and bacteria-positive and FOU children were included for further 
analysis (n = 67), of which four of these were excluded due to sample collected >72 hours from fever 
onset (Figure 5). Of the 51 follow-up blood samples, 31 represented new episodes of febrile 
neutropenia or had clinical signs of symptoms and were therefore excluded as controls. Of the 
remaining 20 samples, 12 children were randomly selected as controls (Figure 5).  
 
3.1.2 Cohort II  
Papers II and III: Children were retrospectively identified and included using the NOPHO-ALL 
registry. Children diagnosed with ALL, treated either within the NOHPO ALL 2000 or the 2008 
protocol at Astrid Lindgren Children’s Hospital between May 2004 and April 2014 were included in 
the study (Figure 5). In paper II, the HR patients were excluded due to the differences in the 
treatment protocols, with a focus on differences in the 6-MP treatment. The HR group was included 
but adjusted for in paper III (Figure 5). Patient characteristics and numbers of episodes of febrile 
neutropenia were retrospectively collected from medical records for both paper II and paper III. End 
doses of 6-MP and numbers of episodes of neutropenia were collected only for paper II, and 
microbiological findings and other infectious parameters during the episodes of febrile neutropenia 
only for paper III. Neutropenia was defined as a neutrophil count ≤0.5 × 109 cells/L. A neutropenia 
episode had to be resolved (≥1.0 × 109 cells/L) before a new episode could be registered. Febrile 
neutropenia was defined as two or more spikes at least 1 hour apart of temperature of ≥38.0°C or a 
single spike of ≥ 38.5°C, with a neutrophil count of ≤0.5 × 109 cells/L at the time of the fever or 
decreasing to ≤0.5 × 109 cells/L within 48 hours of fever onset (58). The patients were followed from 
diagnosis until end of treatment, to relapse, until HSCT, or death.  
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Figure 5: Outline of cohort I, used for papers I and IV and cohort II used for papers II and III. 
   
*Three episodes were redefined from only viral infection to co-infection with virus and bacteria. 
**Four children were excluded due to sampling >72 hours from fever onset.   
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   The selection of sequence variants for papers II and III was made after a thorough literature review 
in 2014 that was updated in 2018 using the following search strategy. A search in the PubMed 
database between 1950-01-01 and 2018-04-30 was performed with the filter “child,” “young adults,” 
“humans,” and “English” for keywords “((acute lymphoblastic leukemia) OR (acute lymphocytic 
leukemia)) AND (polymorphism OR mutation) AND (febrile neutropenia OR infection),” and 271 
papers were identified. Out of the 271 hits, 63 titles were of interest, and 18 abstracts were chosen for 
further reading. An additional search was also made including the keywords “neutropenia” and 
“sepsis,” increasing the number of hits to 313. In addition, earlier known and investigated sequence 
variants within the research group were included. Based on the literature review and prior knowledge 
TPMT, ITPA, and NUDT15 were identified as pharmacogenetic enzymes to further investigate in 
paper II and MBL, TLR4, and IL-1Ra as immunological proteins of interest in paper III. The 
literature review was also updated 2019-12-20 with 325 papers identified (search path “((acute 
lymphoblastic leukemia) OR (acute lymphocytic leukemia)) AND (polymorphism OR mutation) 
AND ((febrile neutropenia) OR (infection) OR (neutropenia) OR (sepsis))”). No new enzymes or 
other proteins of interest for this thesis were identified during this time period. 
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3.2 MOLECULAR ANALYSES 
3.2.1 Real-time PCR 
In paper I, the NPAs were sent to the accredited Karolinska University Laboratory (ISO: 
15189:2012) for analysis according to their standard PCR protocol for detecting respiratory viruses 
(27). In brief, viral nucleic acids were extracted from the NPAs and then analyzed with real-time PCR 
for 15 viruses: HAdV, HBoV, HCoV (NL63/OC43/229E/HKU1), EV, influenza virus (including 
types A(H1N1)pdm09 and B), HMPV, PIV 1-3, RSV, and RV (19). This method can be described as 
semi-quantitative and has not been validated for quantification of viral load. Although viral load 
cannot directly be inferred from the Ct values and should be carefully interpreted, low Ct values still 
indicate higher viral loads. These Ct values were not provided in the medical record but were collected 
retrospectively for paper I in collaboration with the laboratory.  
 
3.2.2 Genotyping  
3.2.2.1 RV/EV genotyping 
For paper I, Sanger sequencing was performed for samples positive for RV/EV by sequencing the 
VP4/VP2 region as previously describes by Dyrdak et al. and Wisdom et al., and the RV/EV species 
and type were determined by maximum likelihood phylogenetic trees constructed using PhyML (232-
234). Through this method, it was possible to distinguish RV and EV in paper I and also determine 
the specific RV genotype. Since some RV still remained present in follow-up samples, the VP4/VP2 
sequencing could determine if the infection was caused by the same RV genotype or a new genotype.  
  
3.2.2.2 Pyrosequencing, TaqMan SNP genotyping assay, and agarose gel electrophoresis  
Different methods were used to determine the genotypes for the investigated proteins and enzymes in 
papers II and III. Pyrosequencing was used for ITPA rs1127354, ITPA rs7270101, NUDT15 
rs116855232, MBL rs1800450, MBL rs5030737, MBL rs1800451, TLR4 rs2737190, TLR4 rs1927911, 
TLR4 rs10759931, and TLR4 rs11536889. Information regarding the presence of TPMT rs1800462, 
TPMT rs1800460, and TPMT rs1142345 variants analyzed by pyrosequencing as part of the clinical 
routine at Linköping University was collected retrospectively (137). Pyrosequencing is a rapid and 
accurate quantification method that can accommodate large samples sizes. Also, pyrosequencing gives 
qualitative sequence data, which confirms that the correct sequence is genotyped. A limitation of this 
method is that only known sequence variants can be detected; however, there are a few examples in 
which the genotype and phenotype can be combined and other less common alleles can be detected 
(through a mismatch with the genotype and phenotype). In paper II, genotyping was performed with 
the TaqMan™ SNP Genotyping Assay for TLR4 rs4986790 and TLR4 rs4986791. To determine the 
sizes of amplicons (how many tandem repeats of the 86-bp sequence) for the IL1RN in paper III, 
agarose gel electrophoresis was used (102). In papers II and III, the sequence variants for the genes 
were pre-determined, and because pyrosequencing was not possible for detection of tandem repeats, 
agarose gel electrophoresis was chosen for IL1RN. When using agarose gel electrophoresis, the 
specific allele in which the sequence variant is located can be detected, giving a specific genotype. 
With pyrosequencing, the result only reveals one specific sequence variant at a specific locus, so when 
investigating several different sequence variants (as with TLR4) within the same gene, the method 
cannot always determine if the sequence variant is located on the same or opposite allele.  
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3.2.3 RNA sequencing 
RNA sequencing is a NGS method that was relatively recently developed (235). RNA sequencing was 
used in paper IV as an expansion to paper I to investigate if the immune response correlated to the 
MDI identified using conventional methods. RNA sequencing was performed using the Illumina 
platform according to the manufacturer’s instructions, and the data were thereafter analyzed in 
collaboration with a bioinformatician (described in the statistical method section below). One initial 
challenge during RNA sequencing was that, even though 5 ml of blood was collected from all 
children, no RNA could be extracted in 20 samples. This was a concern in the study, as RNA from 
blood samples mainly originates from WBCs, and the children included could be severely leukopenic. 
However, in the cases with sufficient RNA the RNA had good quality (RNA integrity number, RIN 
>7). Because many of the methods currently used for pathogen detection still have limitations, the use 
of information from RNA sequencing would be of great interest with regards to clinically diagnosis of 
pathogens. RNA sequencing has the ability to detect novel transcripts and does not require any 
specific transcript probes, it can detect genes with low expression, and it can reveal SNPs in the 
transcribed regions (235). Even though RNA sequencing is a promising method, it still has its 
limitations. One challenge is that the transcriptomes generated require large amounts of data capacity 
to store the information. In addition, the data analysis is a very complex procedure, and no gold 
standard method has been implemented (235, 236).  
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3.3 STATISTICAL ANALYSES 
Data was analyzed using GraphPad Prism 6.0 software (papers I and IV) and R version 3.4.4. 
(papers II and III). A p-value of < 0.05 was considered statistically significant.  
   In paper I, Fisher’s exact test and the Mann-Whitney U test were used for group comparisons of 
categorical and continuous data, respectively. For paper II, the Andersen-Gill model, a proportional 
hazards model allowing for recurrent events, was applied to evaluate the associations between age, 
protocol, treatment intensity (risk group), gender, and sequence variants and the risk of neutropenia or 
febrile neutropenia (237). The function coxph in the R package survival was used to fit the models 
(238, 239). Doses of 6-MP were compared between protocols, risk groups, and genders using 
independent sample t-tests. Pearson correlation coefficients were calculated to assess the correlation 
between the age at diagnosis and 6-MP dose. In paper III, the Andersen-Gill model was also used to 
evaluate the associations between age, protocol, risk group, gender, ALL immunophenotype, and 
sequence variants and the risk of febrile neutropenia and MDI (237). The function coxph in the R 
package survival was used to fit the models (238, 239). Statistical analyses for papers II and III were 
performed in collaboration with a statistician. In paper IV, the analyses were performed in a 
collaboration with a bioinformatician. Samples were mapped using a human reference genome, and 
the data was normalized using DESeq2 (false discovery rate (FDR) <0.05 and fold-change of 1.5 were 
used to identify significant genes). Ingenuity Pathway Analysis (IPA) software was used for pathway 
analysis (Content version: 51963813; Release Date: 2020-03-11; Ingenuity Systems).  
 
3.4 ETHICAL CONSIDERATIONS 
All studies were approved by the Regional Ethical Review boards in Stockholm and Linköping 
(2008/648-31/4, 2009/286-32, 2010/1652-32, 2014/1012-31/4, 2016/442-31/2 and 01-297 Linköping).  
   Children treated for cancer experience intensive treatment and regular repeated sampling. It was of 
importance that our studies would not require additional hospital visits and that sampling would cause 
as little distress as possible. Therefore, samples were taken together with the routine samples as often 
as possible and in some cases previously collected samples were used. In papers I and IV, NPA 
collection could cause minor distress. However, these samples were collected as quickly as possible 
and sometimes as a part of the clinical routine. The results were also provided in the medical records 
for the clinician. The blood samples were always synchronized with other clinical samples. We 
believe that the short discomfort is outweighed by the positive long-term effects (on a group level) of 
increasing knowledge of optimal management of febrile neutropenia, with potentially fewer days of 
in-hospital care and broad-spectrum antibiotics, as well as improved diagnosis. In papers II and III, 
data were retrospectively collected from medical records and results presented on a group level. The 
samples were already collected as part of the clinical routine. This study tested genetic sequence 
variants, which could be seen as a violation of the personal integrity. However, the children had ended 
their treatment when results were published, and patients did not receive any information about the 
results. We believe that increased knowledge about children at risk of infection and children more 
sensitive to specific chemotherapy drugs could lead to more individualized treatment strategies, and 
that such positive outcomes outweigh the possible negative experiences during this study.  
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4 RESULTS AND DISCUSSION  
4.1 ETIOLOGY OF FEBRILE NEUTROPENIA 
Just one decade ago, respiratory viral infections were rarely assessed in children with cancer, 
presumably due to lack of sensitive and rapid detection methods. In addition, respiratory virus was not 
acknowledged as a potential and important cause of febrile neutropenia and diagnostics were mostly 
focused on severe bacterial infection. However, the role of respiratory viral infections during this 
condition has gained interest in the past 10 years. In papers I and IV, the etiology of febrile 
neutropenia was investigated with respiratory viral infection as the main focus. For paper I, PCR and 
blood cultures were used to determine the presence of respiratory viruses and bacterial BSIs, 
respectively. Due to the inherent limitations with both PCR and blood cultures discussed in this thesis 
(e.g., asymptomatic patients and viral remnant findings in PCR and low sensitivity for blood cultures 
in pediatric patients), challenges still remained in interpreting the results generated by these methods. 
Therefore, in paper IV, the MDI and FOU were further investigated to identify a possible 
transcriptional pathway in the innate immune response using RNA sequencing. Unfortunately, the 
results from paper IV revealed that gene-expression profiling is difficult to use in this patient cohort 
and a pathogen-specific innate response was not identified. Despite the current lack of antiviral 
treatment options, a correct diagnosis and increased knowledge of viral infections in children treated 
for cancer is of importance and could lead to a more accurate prediction of the clinical course, 
possibly with fewer days of in-hospital care and decreased use of broad-spectrum antibiotics.  
   
4.1.1 Paper I 
   In paper I, all children admitted to the hospital for febrile neutropenia during a period of 18 months 
(January 2013–June 2014) were asked to participate in the study. Therefore, at least two infectious 
disease seasons were covered during the sampling period. This was of importance with regards to 
respiratory viral infections, since the circulation of most virus follow distinct epidemiological patterns 
and largely vary in incidence over the year (Table 1, p. 7). In total, 54 children with 87 episodes of 
febrile neutropenia were included. One or several respiratory viruses was detected in 45% of all 
episodes. RV was the most commonly detected virus (n = 21, 24%), followed by HCoV (n = 7, 8%) 
and influenza virus (n = 4, 5%). Ct values were collected for the different viruses to estimate viral 
load. The low Ct values in most of the cases (<30 in 27/39, presented in paper I) indicated a high 
viral load. In 86% of the respiratory virus-positive episodes the child also presented with respiratory 
symptoms, providing further evidence that the identified virus was indeed related to the febrile 
episode. In contrast, respiratory symptoms were only presented in 40% and 58% of children with only 
bacterial BSI and FOU, respectively, which was significantly different compared to the virus-positive 
group. However, the bacterial BSI group (n = 5) was relatively small, which must be considered when 
interpreting the results. Follow-up samples were collected in 32 of the 39 virus-positive episodes 
(median time to follow up, 28 days; range, 9-74 days), and as many as 84% had cleared the respiratory 
virus; only HCoV and RV persisted in one and four episodes, respectively. Initially, six RV samples 
remained positive after the regular PCR was performed at the microbiology unit (Karolinska 
University Laboratory), but sequencing of these samples revealed that two of these episodes were a 
new RV genotype. 
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Bacterial BSI was confirmed in eight (9%) episodes. Of these, a respiratory virus was also detected in 
three. The bacteria identified in episodes without viral co-infection were S. epidermidis, coagulase-
negative staphylococci, E. coli, and two S. aureus. The three bacteria co-detected with a virus were 
alpha-hemolytic Streptococcus and two S. epidermidis cases. It should however be noted that blood 
cultures have low sensitivity in pediatric patients (43, 44). Interestingly, all of the children with a 
bacterial BSI were treated for a hematological malignancy.  
 
4.1.1.1 Microbiological findings during febrile neutropenia episodes 
The results from paper I were consistent with previous studies, both for frequency and subtype of 
respiratory virus (52, 65-68, 77, 240, 241) (Figure 6 and Table 2). Koskenvuo et al. performed the first 
study, which included respiratory viral testing in children with febrile neutropenia using PCR, and 
identified a respiratory virus in 44% of the cases (77). Subsequent studies also concluded that 
respiratory viruses could be detected in 45–52% of the febrile neutropenia episodes (52, 65, 66) 
(Figure 6). Similar to our study, respiratory viral findings were more often associated with respiratory 
symptoms (65, 66). In a recently published study by Meena et al., children with episodes of febrile 
neutropenia with respiratory symptoms were considered as cases and children without symptoms as 
 
Figure 6: FOU and MDI during febrile neutropenia episodes in pediatric patients treated for cancer. Gaps 
represent either not reported or no cases. *Also reported four blood-borne viruses which are not included in 
the numbers, **Did not report bacterial BSI, ***Respiratory symptoms/infection were inclusion criteria in 
these studies. 
 
Abbreviations: BSI, bloodstream infection; FOU, Fever of unknown origin; MDI, Microbiological defined infection  
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controls. In the group with respiratory symptoms, 76.5% of the patients had a detected respiratory 
virus (compared to 48.6% in the control group). The correlation between respiratory symptoms and 
viral findings supports the hypothesis that respiratory viral sample collection should be part of the 
routine clinical management in children presenting with respiratory symptoms during febrile 
neutropenia. In paper I, fewer bacterial BSIs were detected compared to previous studies, in which 
such infections have been reported in 13–27% (Figure 6) (52, 65, 77). One reason may be that we 
excluded children with positive blood cultures (n = 5) that were considered as contamination or of no 
clinical relevance by the laboratory staff and the treating physician. Other potential sources of bias 
may be that the children suffering from a bacterial BSI had a more severe condition and therefore 
more often declined participation in the study (no such data available).  
 
4.1.1.2 Asymptomatic infection and prolonged viral shedding   
Certain respiratory viruses have been reported as commonly detected by PCR in asymptomatic 
children and persist weeks after an acute infection, which hampers clinical interpretation (29, 33, 79, 
242). Respiratory viruses and their presence in asymptomatic, immunocompetent children have been 
investigated in a series of studies. Rhedin et al. conducted a case-control study in children presenting 
to the emergency room with respiratory symptoms (29). The control group included asymptomatic 
children at their routine visits at child healthcare centers. The authors identified a respiratory virus in 
35.4% of asymptomatic individuals in the control group, with RV and HCoV the most commonly 
detected viruses in this group. RSV, HMPV, and PIV were only rarely identified in the asymptomatic 
individuals. These results were consistent with those of previous investigations conducted in similar 
patient cohorts (33, 34, 243-245). The authors of these studies concluded that HMPV, PIV, influenza, 
and RSV are likely to play an etiologic role and suggested that findings of RV and HCoV should be 
more carefully interpreted (29, 33, 34, 243-245). To our knowledge, no similar studies investigating 
asymptomatic infections in children treated for cancer have been published. In paper I, the results 
were in line with those of the aforementioned studies in immunocompetent cohorts; RV and HCoV 
were the only viruses identified in children without reported symptoms during febrile neutropenia 
episodes (29, 33, 34, 243-245).   
 
 
 Most commonly detected respiratory 
virus Follow-up samples Persistent virus 
Koskenvuo et al. RV (22%), RSV (11%), HBoV 5%) 27/61 3RV, 1 RSV 
Lindblom et al. RV (17%), HCoV (9%), HAdV (4%) 8/41 2 RV, 1 HCoV 
Suryadevara et al. RV/EV (32%), Influenza (10%), PIV (6%) 15/23 0 
Srinivasan et al. RV (49%), PIV (12%), RSV (11%) 119/193 6 RV, 2 influenza* 
Benites et al.  RV (23%), RSV (9%), HCoV (7%) N/A N/A 
Söderman et al. RV (24%), HCoV 8%, influenza (5%) 32/39 4 RV, 1 HCoV 
Torres et al.  RV (16%), RSV (9%), PIV (6%) N/A N/A 
Aldemir-kocabas et al. RV (16%), RSV (10%), HCoV (10%) 28/43 2 RV, 1 HCoV, 1 PIV 
Meena et al.  RV (25%), HCoV (12%), PIV (12%)** N/A N/A 
 
 
 
 
 
*persistent >100 days 
**combined cases and controls 
 
Abbreviations: EV, Enterovirus, HBoV, Human Bocavirus; HCoV, Human Coronavirus; N/A, Not investigated/reported; 
PIV, Parainfluenza virus; RSV, Respiratory syncytial virus; RV, Rhinovirus  
Table 2: Most commonly identified respiratory viruses and follow-up samples during episodes of febrile 
neutropenia in children treated for cancer.  
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   In paper I, there was no control group. However, the study participants served as their own control, 
as follow-up sampling was performed. This study design identified children still positive for a 
respiratory virus weeks after the first sample was collected. All children who were repeatedly positive 
for RV (n = 4) still reported respiratory symptoms at follow-up, which occurred after ~1.5-7 weeks, 
which raises the question of whether these children had prolonged viral shedding due to their 
immunosuppression. Studies have been conducted following virus-positive children in 
immunocompetent cohorts (79, 242, 246-248). Jartti et al. studied both EV and RV and reported 
shedding times of 2–3 and 5–6 weeks, respectively (79). However, they did not genotype the RV 
samples, so the RV-positive follow-up samples could have represented a new infection because >100 
different RV subtypes are known. Another study by Martin et al. followed a cohort of children at 
daycares with repeated sampling (after 7–10 days) and registered respiratory symptoms (242). They 
identified RV 41 days after symptom debut, HBoV and HAdV after 44 days, and RSV virus after 47 
days. The other viruses detected had a shorter shedding time of 7–26 days (Table 1, p. 7). Hence, 
shedding time appears to differ between viruses even in immunocompetent cohorts, not only in 
immunosuppressed cohorts. Also in this respect, the results are in concordance with those of paper I 
and similar studies that investigated viral infections during febrile neutropenia, during which viruses 
such as influenza, PIV, and HMPV seem to be rare weeks after the acute infection, while RV and 
HCoV are more frequently detected at follow-up (Table 2) (52, 68, 77, 240). In paper I, the shedding 
times for different viruses did not seem to differ from what had been reported in immunocompetent 
children. However, the cohort in paper I was rather small, children included had a higher median age 
than many of those studies involving immunocompetent children, and only a few cases of each virus 
were detected, making it difficult to draw definitive conclusions regarding the shedding times.  
 
4.1.1.3 Limitations 
One limitation in paper I was the lack of a control group. A matched control group of children who 
were neutropenic but without fever would have been desirable to investigate the presence of 
asymptomatic detection of viruses in an immunosuppressed cohort. A control group was included 
early in the study. However, all of these patients developed a fever within a few days from sampling 
and therefore had to be excluded. Due to this issue, the study had to proceed without a control group. 
However, the study participants served as their own control group. Furthermore, the design of paper I 
was not ideal for determining the exact shedding times of different respiratory viruses, as such a study 
would have demanded at least weekly (preferably daily) sampling, which was not possible in this 
study. Lastly, the cohort was rather heterogeneous, with children treated for diverse malignancies and 
different age groups, and children included at different time points of their treatment.  
 
4.1.1.4 Summary 
Paper I added new perspectives to the field; its longitudinal study design followed all virus- positive 
children, presented the Ct values, which helped to further address the respiratory viral findings, and 
sequenced the RV/EV-positive episodes to investigate persistent or reinfection with a new genotype. 
In addition, with the knowledge that: (i) respiratory viral infections are commonly detected, (ii) 
respiratory viruses are mainly cleared within a shorter period (with the exception of RV and HCoV), 
(iii) low Ct values indicate a high viral load, and (iv) the detection rate of bacterial BSI was low, the 
results in paper I strengthen the evidence that the respiratory virus are a common cause of febrile 
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neutropenia episodes. However, some issues still remain: (i) asymptomatic virus detection is common, 
(ii) there is a prolonged shedding time (mainly for RV and HCoV) and (iii) simultaneous infection 
with bacteria occurs wherefore causality could not be proven. Against this background, clinical 
management changes should not be implemented solely based on the results in paper I. One 
remaining challenge is to develop microbiological methods that can correlate a positive viral sample 
with an actual infection. Paper IV was an attempt to further address the etiological role of the viral 
and bacterial findings during episodes of febrile neutropenia.   
 
4.1.2 Paper IV 
Paper IV took advantage of the same cohort used in paper I for all children where a blood sample 
was collected within 72 hours from fever onset (n = 63). In 20 of these, there were insufficient 
amounts of RNA, leaving 43 case samples collected from 35 unique individuals (Figure 5, p. 25). A 
majority of the children diagnosed with only a bacterial infection did not express sufficient amount of 
RNA (60%) (Figure 5, p. 25). The control samples were collected in the same cohort, but sampled at a 
time when the children were asymptomatic and 12 episodes, representing 12 unique individuals were 
included in the final analysis (Figure 5, p. 25). First, the RNA insufficient group (n = 20) was 
compared to the case group (n = 43) and lower total WBC count and ANC (p-value <0.001 for both), 
a higher C-reactive protein (CRP) and higher number of days of antibiotics (p-value <0.01 and <0.05, 
respectively) were identified for the RNA insufficient group. Second, the different case groups (viral, 
co-infection and FOU, respectively) were compared to the control group. Results showed a higher 
WBC count and ANC in the control group compared to viral and FOU (presented in paper IV). When 
comparing the control group to the co-infection group, only a higher ANC in the control group was 
identified (presented in paper IV). These findings were expected, as the samples from the control 
group were collected at a point in time when the children are usually not neutropenic.  
   The case groups with viral, co-infection, bacterial and FOU were then pairwise compared to the 
control group to investigate whether a specific transcriptional profile in the immune response during 
the febrile neutropenia episodes could be identified as compared to when the children were 
asymptomatic. For the viral and FOU group, the majority of differentially expressed genes were up-
regulated (178/231 and 261/443, respectively), while for the co-infection group the majority was 
down-regulated (124/219). For bacterial infection compared to the control group, there were only two 
genes that were differently expressed and therefore no further analysis was performed in this group. 
When performing pathway analysis for the viral, co-infection and FOU groups, none of the up-
regulated genes could be enriched to the innate immune response for any of the groups. Interestingly, 
for the co-infection group, genes involved in the IFN signaling pathway was identified as the top 
ranked pathway of down-regulated genes (Figure 7). This results was surprising and contradictory to 
both our hypothesis as well as earlier published findings in immunocompetent children (229). 
 
4.1.2.1 Innate immune signatures in children 
A few studies have investigated blood innate immune signatures in children with fever with a 
diagnostic perspective, mainly by using microarrays. Microarrays constitute a slightly different but 
comparable method to RNA sequencing because both methods measure the transcriptome (249, 250). 
One of the first studies performed in a pediatric cohort was by Ramilo et al., in which the  
  35 
 
 
 
authors demonstrated that they could distinguish children with acute infection by influenza, E. coli, S. 
aureus, and S. pneumoniae using gene expression patterns. Another study by Hu et al. included both 
febrile children (with different viruses and bacterial infections) and afebrile children (both positive for 
viral infections and negative controls) (229). The latter study could identify specific signatures that 
could distinguish between viral and bacterial infections. Interestingly, the transcriptional profiles were 
different between febrile and afebrile children positive for the same viruses, and the afebrile group 
was indistinguishable from the profile of virus-negative children. This was a relevant finding, as one 
of the issues discussed in this thesis is how to interpret the viral findings, especially those of 
respiratory viruses. Such results could therefore be of practical importance to distinguish 
asymptomatic and symptomatic infections (229). In a later study by Herberg et al., a larger cohort was 
included, and both test and validation sets were assessed. The authors were able to identify a 2-
transcript signature to distinguish viral from bacterial infection. Expression of IFI44L (viral) and 
FAM89A (bacterial), were increased as compared to healthy children. These specific 2-transcript 
signatures were also identified in subsequent studies in febrile children (251, 252). Another important 
issue to address is how the WBC count affects the results from transcriptomics. Hu et al. was not able 
to identify a correlation between the total WBC count and the gene expression levels. However, the 
Figure 7: IFN-signaling pathway for co-infection versus control group. Green indicates the significant down-
regulated genes (figure generated from IPA) 
Abbreviations: GAS, gamma-activated sequence; IFN, Interferon; IFNγ, Interferon gamma, IRF, Interferon regulatory factors; 
JAK, Janus Kinas; NF-kB, Nuclear factor kappa-light-chain-enhancer of activated B cells; OAS, Oligoadenylate synthetase; 
PIAS1, Protein Inhibitor Of Activated STAT 1, SOCS1, Suppressor of cytokine signaling 1; STAT, Signal transducer and 
activator of transcription. TC-PTP, T-Cell Protein Tyrosine Phosphatase, Tyk, Tyrosine Kinase 2.  
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authors did identify that the expression of specific clusters of genes were associated with ANC, 
lymphocyte, and monocyte counts and therefore suggested that the clusters might be activated by 
specific cells types (229).  
   In paper IV, we wanted to investigate if gene-expression profiles could be identified in a cohort of 
children treated for cancer, as we were unsure of whether these children would have a detectible 
immune response with these methods due to immunosuppression. First, almost one third of the 
samples collected did not contain sufficient amounts of RNA to be able to perform the analysis, due to 
low amount of WBC count and ANC. Second, even in those samples with sufficient RNA, we could 
not identify any specific innate signatures for the different microbiological pathogens. To be able to 
correctly diagnose bacterial infections during febrile neutropenia is of utter most importance, as many 
of the treatment related deaths are due to these infections. However, in our study, the cases with 
bacterial infection were overrepresented in the group with insufficient RNA for RNA sequencing and 
when comparing the bacterial group with sufficient RNA to the control group there were only two 
genes that differentiated (Figure 5), which hampers the interpretation of the results. As for respiratory 
virus roles during these episodes, the results from paper IV could not answer whether the detected 
virus in nasopharynx was indeed causing the febrile neutropenia episode as no viral specific gene-
expression signatures in blood were identified. The results that the co-infection group had a down-
regulated innate immune response was, as mentioned, a surprise. We cannot fully explain the results 
identified. Plausible theories that could explain the findings are that the innate immune cells were 
redistributed to the affected tissues and therefore not abundant in the circulation or that the immune 
response was downregulated due to the immunosuppressive treatment. Lastly, it is still not fully 
known how chemotherapy affects the immune response. Is it possible that the chemotherapy affects 
the few remaining cells still present, and hamper the generation of a proper immune response? Is that 
the reason why we did not see the same pattern as in studies with immunocompetent children? In an 
earlier study performed by us, prolonged viral shedding did not seem to be a major issue in this 
patients cohort; hence, these children do have an immune response that is able to clear respiratory 
viruses (69). Therefore, is the immune response at the local site sufficient and could specific innate 
immune signatures be detected in mucosal tissue? Yu et al. identified an IFN response at the local site 
during viral infection, much like the signature in blood. Therefore, in future studies both blood 
samples and samples from relevant mucosal sites should be collected to fully evaluate the response in 
this patient cohort.  
 
4.1.2.2 Limitations 
In general, there is still limited data from the use of blood innate immune signatures as a diagnostic 
tool and the present study was also subject to a few limitations that should be considered. First, the 
samples size was small and the cohort was heterogeneous as it consisted of children treated for 
different cancer diagnoses. Another issue was that one-third of the blood samples did not contain 
sufficient RNA and therefore had to be excluded. Therefore, based on the limited size of our study, it 
would be difficult to assess this method as a diagnostic tool, since there would be a significant risk 
(over 30%) that the samples would not contain sufficient amounts RNA to perform the analysis.  
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4.1.2.3 Summary  
Results from paper IV did not reveal similar transcriptional profiles as in cohorts of febrile 
immunocompetent children. In fact, results indicate that gene-expression profiling is difficult to use in 
a cohort of children treated for cancer, since the amount of RNA from blood was insufficient and 
blood immune response seems to differ from that of otherwise healthy children. Due to these issues, 
the feasibility of using transcriptomics in children presented with febrile neutropenia during cancer 
treated remains challenging. Additional studies are needed to further investigate this response and the 
feasibility of using gene-expression profiling as a diagnostic method in this patient cohort, preferably 
using both local and blood samples.   
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4.2 RISK FACTORS OF FEBRILE NEUTROPENIA 
In papers II and III, risk factors of side effects during treatment for ALL were assessed by 
investigating genes coding for important enzymes and proteins in drug metabolism and the immune 
system. Both papers included a homogeneous cohort of children treated for ALL within the NOPHO 
ALL 2000 and 2008 protocols. In paper II, the main focus was enzymes important in drug 
metabolism (i.e., TPMT, ITPA, and NUDT15). These enzymes were of interest because the hypothesis 
stated that sequence variants in the genes increased the risk of neutropenia and febrile neutropenia and 
also led to lower end doses of 6-MP. Paper III assessed the characterization of microbiological 
findings during episodes of febrile neutropenia in children during the entire 2.5 years of treatment for 
ALL. In addition, in paper III, investigated proteins important in the immune system (i.e., TLR4, 
MBL, and IL-1Ra) with the hypothesis that sequence variants in these genes may lead to an increased 
risk of episodes of febrile neutropenia and associated MDI. The knowledge of a child’s individual risk 
of febrile neutropenia and specific infections during these episodes could improve risk stratification 
during cancer treatment and thereby prevent these events with regard to dose reduction in children 
deficient in drug metabolism genes as well as to tailor prophylaxis.  
 
4.2.1 Paper II  
In paper II, 102 children were included in the final analysis. Younger age and the NOPHO ALL 2008 
protocol were associated with neutropenia and febrile neutropenia during the entire treatment period 
and the maintenance II phase (only associated with age). Therefore, these factors were adjusted for in 
the final analysis. Both factors were expected because infections are more common at young age (with 
fever as a consequence), and the NOPHO ALL 2008 protocol contained slightly higher doses of 
chemotherapy during the entire treatment period but not during the maintenance II phase. Because 6-
MP and MTX are the only drugs administered during the maintenance II phase, investigating this 
phase separately was of great interest. The results from paper II revealed that children deficient in 
any of the TPMT sequence variants had a decreased risk of both neutropenia and febrile neutropenia 
during the maintenance II phase. In fact, none of the 10 patients with at least one TPMT sequence 
variant had any episodes of febrile neutropenia during the maintenance II phase. These results were 
unexpected because the hypothesis stated that, due to dose reduction, TPMT-deficient children would 
have an increased or the same risk of neutropenia and febrile neutropenia compared to TPMT-wild-
type children. No significant difference in 6-MP end dose was identified for TPMT-deficient children 
as compared to TPMT wild-type children (mean end doses 53.0 mg/m2 and 61.4mg/m2, respectively; 
p = 0.098). Another notable result in paper II was that children deficient in NUDT15 received lower 
end doses of 6-MP (mean end dose 40.4 mg/m2; p = 0.0097), which was in line with our hypothesis. A 
NUDT15 variant is rare in European cohorts, reported only in 0.2% of the population (128). The 
frequency of 4% observed in the study was therefore higher than expected. It should be emphasized 
that these results must be carefully interpreted because of the small sample size. For ITPA, the results 
revealed that children deficient in ITPA rs1127354 had a decreased risk of febrile neutropenia during 
the entire treatment period (unadjusted). These results were also unexpected and contrary to our 
hypothesis. No significant associations with the end doses of 6-MP and ITPA deficiency were seen.  
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4.2.1.1 The role of TPMT in children treated for ALL 
Early studies investigating TPMT deficiency revealed that patients had an increased risk of 
myelosuppression and were more intolerant to 6-MP treatment (Table 3) (139). This resulted in 
implementations of recommended 6-MP dose reduction for deficient patients in many of the ALL 
treatment protocols. Subsequent studies also found TPMT-deficient patients to be less tolerant to 6-
MP, and they receive lower doses when adjusted according to WBCs (107, 119, 128) (Table 3). In 
contrast, the analysis in paper II showed TPMT-deficient children to have decreased risks of 
neutropenia and febrile neutropenia during the maintenance II phase. One reason for this observation 
could be that the clinicians were aware of the child’s TPMT genotype and more careful when 
increasing the 6-MP dose (adjusted according to WBC during maintenance II). There was a trend 
towards lower end-doses of 6-MP in TPMT-deficient children as compared to wild-type patients, but 
this was not statistically significant. However, solely based on the results from paper II, we cannot 
fully understand the decreased risk of these conditions, and this need to be addressed in larger cohorts. 
 
4.2.1.2 The role of NUDT15 in children treated for ALL 
In study populations of Asian origin, the frequency of TPMT deficiency is low and the NUDT15 
deficiency is higher. Consequently, NUDT15 has become a topic interest during 6-MP treatment in 
this population (105, 128, 138). NUDT15 was identified as a potent predictor for myelosuppression 
and 6-MP intolerance, and dose reduction is often needed in deficient patients (Table 3) (119, 125, 
128, 160, 161). Therefore, recommendations to detect sequence variants in NUDT15 and make dose 
adjustments in NUDT15-deficient patients have been implemented in some of the newer ALL 
treatment protocols (162). Even though NUDT15 was rarely identified in paper II (n = 4), the results 
indicated the same conclusion: patients deficient in NUDT15 were more intolerant to 6-MP and 
therefore received lower end doses. In paper II, no correlation with neutropenia or febrile neutropenia 
was identified. This finding could possibly be explained by the fact that deficient children received 
lower doses, hence neutropenia did not occur. Another factor that could explain the findings is that the 
sample sizes were too small (n = 4), and therefore, differences were not discovered. 
 
4.2.1.3 The role of ITPA in children treated for ALL   
Studies investigating ITPA have presented contradictory results. Some identified a correlation between 
reduced doses of 6-MP and an increased risk of febrile neutropenia or more severe febrile neutropenia 
episodes, while other have not identified any such association (Table 3) (107, 118, 119, 123, 125, 152, 
154, 155). In paper II, no increased risk of neutropenia or febrile neutropenia or dose reduction of 6-
MP was identified. On the contrary, ITPA rs1127345 was associated with decreased risk of febrile 
neutropenia (unadjusted for age at diagnosis and treatment protocol). Interestingly, Hareedy et al. 
reported that children with wild-type ITPA rs1127345 had an increased risk of leukopenia compared 
to deficient patients (Table 3). Similar results were described in a study by Ban et al. where ITPA 
rs1127345 was investigated in patients with inflammatory bowel disease treated with 6-MP (reported 
as not significant) (253). However, the different degrees of immunosuppression between 
inflammatory bowel disease patients and children treated for ALL makes the results difficult to 
compare. Due to the contradicting results in earlier studies as well as our own study, and as thiopurine 
metabolism is complex, the role of ITPA still needs further evaluation.  
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STUDY SEQUENCE VARIANT COUNTRY 
LOW 
WBC FN DOSES 
Relling et al.  TPMT USA ↑ 1 → ↓ 
Stocco et al.  TPMT USA N/A → ↓ 
Yang et al.  TPMT USA N/A N/A ↓ 
Liang et al.  TPMT China N/A N/A ↓ 
Zgheib et al.  TPMT Lebanon N/A N/A ↓ * 
Gerbek et al.  
 TPMT Denmark N/A N/A N/A 
Zhou et al.  
 TPMT China N/A N/A ↓ 
Moradveisi et al.  TPMT 
 Lebanon and Iran N/A ↑
** ↓ * 
Stocco et al. ITPA USA N/A ↑ → 
Tanaka et al. 
 ITPA Japan → N/A ↓ 
Azimi et el.  ITPA Iran ↑2 N/A N/A 
Hareedy et al.  
 ITPA Egypt 
↑ a, 1,3 
↓ b,3*** N/A N/A 
Chiethong et al.  ITPA Thailand → N/A → 
Gerbek et al.  
 ITPA Denmark N/A N/A N/A 
Zhou et al.  
 ITPA China N/A N/A → 
Moradveisi et al.  ITPA Lebanon and Iran N/A ↑** ↓ 
Tanaka et al.  NUDT15 Japan ↑ N/A ↓ 
Yang et al. NUDT15 USA N/A N/A ↓ 
Chiethong et al.  NUDT15 Thailand ↑ N/A ↓ 
Liang et al.  NUDT15 China N/A N/A ↓ 
Moriyama et al.  
NUDT15 
Guatemala, 
Singapore and 
Japan 
N/A N/A ↓ 
Suzuki et al.  
 NUDT15 Japan → N/A ↓
**** 
Moriyama et al.  NUDT15 Japan N/A N/A ↓ 
Zgheib et al.  
 NUDT15 Lebanon N/A N/A ↓
* 
Yi et al.  
 NUDT15 Korea ↑
3 ↑ ***** ↓ 
Zhou et al.  
 NUDT15 China ↑ N/A ↓ 
Moradveisi et al.  NUDT15 Lebanon and Iran N/A → * ↓* 
      
 
↑: Increase/higher levels, ↓ Decrease/lower levels, → No association 
*Few deficient patients, **combined ITPA and TPMT and increased onset of FN, ***wild-type alleles higher risk 
as compared to heterozygous, ****<7years of age, *****In children with two defect alleles 
1Neutropenia, 2Myelosuppression, 3Leukopenia 
a rs 7270101, b rs1127354  
 
 
Abbreviations: FN, Febrile neutropenia; ITPA, inosine triphosphate pyrophosphatase, N/A, not investigated/reported; 
NUDT15, Nudix hydrolase 15; TPMT, Thiopurine methyltransferase; WBC, White blood cells.    
Table 3: Sequence variants in TPMT, NUDT15 and ITPA and risk of neutropenia, febrile neutropenia and 
affected doses of 6-MP during pediatric ALL treatment  
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4.2.1.4 Combined sequence variants in TPMT, NUDT15, and TPMT 
Hypothetically, would the presence of multiple sequence variants increase the risk of side effects even 
more? In paper II, eight children had >1 sequence variant in TPMT, ITPA and NUDT15 and these 
tended to have lower 6-MP end doses (Figure 8). Interestingly, one child had both TPMT and 
NUDT15 deficiency and a low 6-MP end dose of ~30 mg/m2/day. Liang et al. and Zhou et al. reported 
that children with both a deficiency in TPMT and NUDT15 (n = 4 and n = 1, respectively) also had 
doses of 6-MP ~30 mg/m2/day. However, it was not possible to perform any statistical calculations 
based on this data due to the small sample sizes in each group in paper II. 
4.2.1.5 Limitations 
Some limitations in paper II need to be addressed. First, the study was of retrospective design, and 
information was collected from medical records. However, strict pre-defined rules for the definition of 
neutropenia, febrile neutropenia, and end doses of 6-MP were used. Due to the retrospective design, 
the 6-MP metabolites (TGNs) were not available, although this would have provided valuable 
information. Another issue is that only the most common sequence variants in TPMT, ITPA, and 
NUDT15 were investigated. Therefore, misclassification bias was possible, in which children with 
more uncommon variants were classified as “wild-type” by default (137). However, studies have 
determined that the three most prevalent TPMT sequence variants yield ~95% concordance between 
genotype and phenotype and therefore the risk of misclassification was relatively small (135, 137). In 
paper II, a few children without any of the sequence variants detected still had very low 6-MP doses 
(one patient with as low as ~20 mg/m2/day), and these children may have had another sequence 
variant not investigated in the study (Figure 8).  
Figure 8: Genetic sequence variants in TPMT, ITPA and NUDT15 and 6-MP end doses. 
 
Abbreviations: ITPA, inosine triphosphate pyrophosphatase; NUDT15, Nudix hydrolase 15; TPMT, Thiopurine 
methyltransferase.   
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4.2.1.6 Summary 
Paper II contributed to the field by investigating TPMT, ITPA, and NUDT15 in a cohort of pediatric 
patients treated for ALL in Sweden. To the best of our knowledge, ITPA and NUDT15 had not been 
previously investigated in this cohort within the Nordic countries. Most studies have concluded that 
TPMT and NUDT15 play important roles in 6-MP metabolism and the risk of side effects (Table 3). 
However, the role of TPMT and ITPA deficiency for febrile neutropenia was not fully clarified in 
paper II. In addition, NUDT15 seem to play a role for the treatment of 6-MP, resulting in lower end 
doses of 6-MP. However, due to the relatively small cohort and the low prevalence of some of the 
genetic variants investigated, additional larger studies are needed.  
 
4.2.2 Paper III 
In paper III, 122 children were included in the analysis (Figure 5, p. 25). A total of 380 episodes of 
febrile neutropenia were identified, which 64 represented solely viral infection (16.8%), 61 (16.1%) 
solely bacterial BSI, 2 (0.5%), or solely IFD, and the fever was defined as FOU in 240 episodes (one 
episode was undefined) (Figure 6). Nine episodes were mixed bacterial BSI and virus, six episodes 
had both Gram-positive and Gram-negative bacteria identified, and four episodes were IFD mixed 
with either bacterial BSI and/or virus. During the study period, two (2%) children died due to 
infection-related causes. The risk of febrile neutropenia and MDI during these episodes was associated 
with age, treatment protocol (NOPHO 2008 protocol), and treatment intensity (HR group, with 
exceptions for viral infections and Gram-positive bacteria). These factors were adjusted for in the final 
analysis. The results were similar to those of a study by Li et al., in which both age and HR groups 
were associated with fever and MDI in children treated for ALL (55). When investigating sequence 
variants in genes coding for TLR4, MBL, and IL-1Ra, sequence variants in TLR4 rs10759931 and 
rs11536889 were associated with an increased risk of viral infections. In addition, children with either 
the IL1RN*2 or IL1RN*3 genotype had a decreased risk of bacterial BSIs. A sub-analysis of children 
with bacterial BSI showed that genotype IL1RN*2 had a decreased risk of Gram-negative bacteria 
infection, while children with IL1RN*3 did not have any Gram-positive bacteria detected. The sub-
analysis of the bacterial BSIs also revealed that children with sequence variants in TLR4 rs4986791 
had a decreased risk of infection with Gram-negative bacteria.  
 
4.2.2.1 Microbiological findings during episodes of febrile neutropenia  
There are still limited data on infection-related complications during ALL treatment. Only two studies 
investigating febrile neutropenia and infections during the entire ALL treatment could be identified 
(55, 56). These studies reached different conclusions for the most commonly detected agents; Inaba et 
al. reported respiratory tract infections to be the most prevalent, while Li et al. found that bacterial 
BSIs were the most common infections. However, one issue with these studies is that the they 
reported episodes of febrile neutropenia and then infectious agents during treatment separately. This is 
one of the differences compared to paper III, in which the strength of the study is that all infectious 
agents detected during febrile neutropenia episodes were reported. In the clinic, febrile neutropenia is 
a dreaded complication since it can rapidly worsen into severe conditions if not immediately treated. 
The reported bacterial BSIs in paper III were in line with earlier studies reporting bacterial BSIs 
during cancer treatment, even though those studies did not follow the same children during the entire 
treatment period (Figure 6, p. 31) (52, 55, 65, 254). As discussed in paper I, bacterial BSIs do not 
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seem to be that common (<30%). Despite these low numbers, all children with febrile neutropenia 
receive broad-spectrum antibiotics ranging from a median/mean of 4–10 days and are treated at the 
hospital for a median of 4–8 days (52, 65-69). The viral infections reported in paper III were lower 
both compared to paper I and to earlier studies with reports of 44-52% (Figure 6, p. 31). The main 
reasons for this discrepancy is probably that the testing for respiratory viral infections in paper III 
was not as stringent and the testing was not performed in all episodes of febrile neutropenia as part of 
the clinical routine together with the fact immunofluorescence was the method used for detection of 
respiratory virus at the Karolinska laboratory during the first part of the study period. One major issue 
still remains: in ~40–70% of the episodes of febrile neutropenia, no cause of the fever could be 
identified wherefore those episodes were defined as FOU (Figure 6, p. 31) (52, 55, 56, 65, 66, 77). 
The results from both paper I and paper III highlight the importance of developing rapid and more 
sensitive methods for the detection and interpretation of microbiological agents during febrile 
neutropenia. This would facilitate the implementation of more individualized treatments, leading to a 
decrease in days of antibiotic treatment and in-hospital care.  
 
4.2.2.2 The role of TLR4 in children treated for ALL 
Studies investigating TLR4 sequence variants have mainly been conducted in adults treated for 
malignancies (181, 202). These studies have identified sequence variants in TLR4 as a potential risk 
factor of Gram-negative BSIs and as carrying increased risks of sepsis and pneumonia (Table 4) (181, 
202). However, similar data for the role of TLR4 in immunosuppressed children is scarce. Miedema et 
al. investigated a pediatric cohort and found four different TLR4 sequence variants that independently 
increase the risk of neutropenia during ALL treatment and concluded that additional studies were 
needed to evaluate the risk of febrile neutropenia in TLR4-deficient children. In paper III, two 
sequence variants in TLR4 were associated with an increased risk of viral infections, and these two 
were the same as identified in Miedema et al. This raises the following questions: does the viral 
infection increase the risk of neutropenia, or vice-versa? Or, are the two conditions not correlated? To 
investigate neutropenia episodes in our cohort to address these questions would have been interesting. 
TLR4 is known to bind LPS present on Gram-negative bacteria, even though it is also an important 
receptor for recognizing specific viruses (217, 255). However, the role of all the sequence variants and 
the effect on phenotype and loss of TLR4 receptor function is not fully understood, and studies in this 
area have been difficult to identify. In addition, the different sequence variants of TLR4 in paper III 
included sequent variants in promoter, exons, and intronic elements of the genes. Therefore, 
challenges remain in interpreting the results regarding TLR4 in a clinical setting. 
 
4.2.2.3 The role of MBL in children treated for ALL 
MBL deficiency has been investigated in several different studies during pediatric cancer treatment. 
However, due to inconsistent results, there are still no conclusions of whether this protein plays a role 
during episodes of febrile neutropenia (Table 4) (181-184, 186, 256, 257). Dommett et al. and Pana et 
al. reported that MBL-deficient children have an increased risk of multiple episodes of febrile 
neutropenia and infections (186, 257). These results were not reproduced in paper III, and no 
associations between MBL deficiency and episodes of febrile neutropenia or MDI during these 
episodes were identified. The results in paper III were in line with studies by Neth et al., Frakking et 
al., and Lausen et al. in that neither identified a correlation to febrile neutropenia nor infectious 
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episodes (183, 184, 256). However, none of those studies followed the children during the entire 
treatment period, and with the exceptions of Pana et al. and Lausen et al., studies have used 
heterogeneous cohorts of children treated for different types of malignancies (181-186). The 
inconsistent follow-up time and heterogeneous cohorts have hampered the interpretation of MBL’s 
role during febrile neutropenia and infectious episodes. Therefore, the results in paper III, with both a 
homogeneous cohort of children and follow-up during the entire ALL treatment period, contributes to 
the field. The findings suggest that MBL does not play a major role during episodes of febrile 
neutropenia and specific infections during these episodes.   
 
4.2.2.4 The role of IL-1Ra in children treated for ALL 
There are limited data on the role of IL-1Ra in children with cancer and risk of febrile neutropenia, 
and a study conducted by Zapata Tarres et al. was one of the few identified. Children treated for ALL 
were included, and the authors identified associations with the genotype IL1RN*2 and the risk of 
septic shock. This finding was contrary to the results from paper III, in which IL1RN*2 and 
IL1RN*3 were associated with a decreased risk of bacterial BSIs. These findings were not expected 
and opposed our hypothesis. However, when starting to thoroughly review the literature, an interesting 
study by Danis et al. was identified. They investigated IL-1Ra immunocompetent individuals and 
suggested that sequence variants in the IL-1Ra gene not only affect the IL-1Ra protein, but also the 
IL-1α protein, and proposed that either the gene directly affects IL-1α production or the two alleles  
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Results 
Lausen et al. MBL 136 P ALL 50d No association* 
Neth et al.  MBL 100 P Mixed** 6m Increased days of febrile neutropenia 
Frakking et al.  MBL 110 P Mixed** 13m No association* 
Pana et al.  
MBL 44 P ALL I-MT 
Increased risk of bacterial infection 
Longer duration of febrile neutropenia 
Dommett et al.  
MBL 269 P Mixed** 12m 
Multiple episodes of febrile neutropenia 
Multiple infections during febrile neutropenia 
Fekete et al.  MBL 107 P Mixed** 2y Shorter period of fever 
Pehlivan et al.  MBL 
 
120 A ALL/AML N/A 
Increased risk of BSI and Gram-neg bacteria 
Higher mortality during febrile neutropenia 
Miedema et al.  TLR4 194 P ALL MT Increased risk of neutropenia*** 
Schnetzke et. al  TLR4 155 A AML I Increased risk of sepsis and pneumonia 
Pehlivan et al. TLR4 120 A ALL/AML N/A Increased risk of Gram-negative BSI 
Pehvlivan et al. IL-1Ra 120 A ALL/AML N/A No association* 
Zapata Tarres et al. IL-1Ra 57 P ALL 2.5y Increased risk of septic shock**** 
* No significant differences between sequence variants and the investigated risk events were identified., **Refers 
to different hematological- and/or solid malignancies, ***Associated with rs10759931, rs11536889, rs1927911 
and rs6478317, ****Associated with the IL1RN*2 variant.  
 
Abbreviations: A; adults, ALL, acute lymphoblastic leukemia, AML; Acute myeloid leukemia, BSI, bloodstream infection; d; 
days, I; induction, IL-1Ra; interleukin-1 receptor antagonist, m; months, MBL; mannose binding lectin, MT; maintenance, 
N/A; Not reported, P; pediatrics, TLR4; Toll-like receptor 4, y; years 
 
Table 4: Summary of studies investigating genetic sequence variants in MBL, TLR4, and IL-1Ra and the risk of 
neutropenia, febrile neutropenia and MDI during pediatric cancer treatment 
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occur in linkage disequilibrium (i.e., often inherited together). Similar results were also presented by 
Hurme et al. (209). If these two ILs are both affected in IL-1Ra deficiency, does this increase or 
decrease the host’s inflammatory response? Is an increased inflammatory response positive or 
negative for the host, as sepsis is not only induced by the bacteria itself but also by the massive 
inflammatory immune response? And is this response the same in immunosuppressed patients? Was 
our hypothesis correct? When further reviewing the literature, another issue emerged. Contradictory 
results regarding the effect on the phenotype (production of IL-1Ra) was identified for the IL1RN*2 
allele. Danis et al. reported that healthy controls had higher levels of IL-1Ra than patients carrying 
IL1RN*2, while Arnalich et al. reported the opposite in a cohort of patients with sepsis. The immune 
response is very active during sepsis, and one explanation of the different results may be that because 
IL-1Ra is an antagonist, the production of this protein is suppressed during sepsis, resulting in its 
lower levels. As paper III only focused on the genotypes of the IL-1Ra gene and not levels of protein, 
these questions are difficult to address. 
 
4.2.2.5 Limitations 
Some obstacles must be overcome when obtaining clinical data retrospectively from medical records. 
Important data may not be documented. An optimal study design would have been prospective; 
however, to be able to include as many patients in Stockholm for paper III, the study would have 
needed to proceed for at least 12 years. To optimize our retrospective study design, we developed 
strict pre-defined criteria to determine whether episodes of febrile neutropenia and microbiological 
findings should be included. In addition, two independent clinicians controlled the included episodes 
and microbiological findings, to ensure that the same criteria were used. Another limitation was that 
the genotype for TLR4 was not assessed because seven different sequence variants were investigated, 
and pyrosequencing could not determine the specific haplotype. Also, as previously mentioned, the 
phenotypes for many investigated TLR4 sequence variants are not known, making it difficult to assess 
if all the investigated sequence variants in TLR4 affect the receptor equally. As in paper II, only the 
most common and earlier reported sequence variants in the TLR4, MBL, and IL-1Ra genes were 
investigated. Therefore, misclassification bias was possible, in which children with more uncommon 
variants were incorrectly classified as “wild-type”. Ultimately, protein levels of MBL and IL-1Ra 
would have been ideal to compare to their genotypes, but this was not possible due to the study 
design.  
 
4.2.2.6 Summary 
Viral infections were the most commonly detected infectious agent. However, the majority of the 
episodes were still defined as FOU. To correctly address the etiology of febrile neutropenia episodes, 
a prospective study with samples for bacterial, viral, and fungal infections at every episode is needed. 
Paper III is one of the first studies investigating TLR4, MBL, and IL-1Ra in a homogeneous cohort 
and that follows children treated for ALL during the entire treatment period. MBL appears to play a 
minor role during episodes of febrile neutropenia during pediatric ALL treatment. However, the roles 
of TLR4 and IL-1Ra need to be further investigated due to the complexity of the proteins and limited 
knowledge of how sequence variants affect phenotype. Therefore, additional prospective studies in 
larger cohorts that measure protein levels at the time of the fever would be of great interest before 
drawing any major conclusions. 
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4.3 ETIOLOGY AND RISK FACTORS FROM A CLINICAL PERSPECTIVE  
4.3.1 How to manage children presenting with febrile neutropenia  
Febrile neutropenia is a potentially lethal condition and often requires rapid assessment when 
suspected in the emergency room. Bacterial BSIs and IFDs are dreaded causes of the condition and 
sepsis can develop within hours from symptom onset in neutropenic patients. However, relatively few 
of these episodes develop into severe sepsis, and today the mortality rate due to infections is ~1–2% 
(56). The initial management with rapid administration of broad-spectrum antibiotics is probably why 
the outcome has improved for this condition. Respiratory viruses are the most common 
microbiological findings during febrile neutropenia episodes, often causing mild disease. Notably, 
there are still many episodes for which no cause of the fever can be identified. Despite this fact, all 
children receive many days of treatment with broad-spectrum antibiotics and days of in-hospital care. 
Hence a more individualized risk prediction model for the febrile neutropenia episodes is needed. The 
question is: what is a safe approach to predict the risk of severe episodes while decreasing the days of 
broad-spectrum antibiotics and in-hospital care? After approximately 48 hours (when results from 
blood cultures usually are received), changing the management of these episodes might be possible. 
Many different prediction models have been developed to try to risk stratify febrile neutropenia 
episodes (60, 258-261). Such models have not yet been thoroughly investigated and implemented in a 
safe manner in a clinical setting (62). Implementation of models would improve the management of 
this frequent complication during childhood cancer treatment. There are several different predictive 
variables that can be included in these models, including cancer diagnosis, treatment intensity phase 
and acute phase proteins. Microbiological findings and sequence variants in genes coding for different 
immune proteins/enzymes could also be considered in such prediction models to identify the children 
at high risk of severe infection who need to continue antibiotic treatment.  
   One of the challenges during my doctoral studies has been to answer the following questions: How 
does one interpret respiratory viral findings during febrile neutropenia episodes? Is it safe to withdraw 
antibiotics if a respiratory virus is detected during an episode? The methods used for respiratory virus 
detection in paper I are the same used in the clinic today. Still, difficulties remain in interpreting the 
results from positive respiratory viral findings, especially RV, EV, HCoV, HBoV, and in some cases, 
HAdV. In addition, all the episodes of FOU are in need of further investigation; what is the actual 
cause of the fever? We hoped that the results from paper IV could bring us closer to the answers. 
Unfortunately, paper IV could not address the outstanding issues, as the results indicated that these 
children did not have the same innate-immune-response signature as otherwise healthy children. 
However, we only investigated the immune response in blood. Yu et al. compared the immune 
response in blood and in the nasal compartment in children with respiratory viral infection and 
asymptomatic children (262). The authors were able to identify a local innate response in symptomatic 
children that were not present in the asymptomatic groups and identified both in blood and nose. 
However, the response also differed between the nose and blood, which the authors explained as the 
epithelial cells activate the immune response when they are infected themselves, whilst immune cells 
in blood are activated as a response to an infection. Nevertheless, all this indicates that by using gene-
expression profiling it is possible to differentiate symptomatic from asymptomatic respiratory 
infections and that samples from relevant mucosal sites would be of value.   
   So, how can we improve management of an episode of febrile neutropenia today? One initial 
suggestion is that respiratory viral testing should be considered as part of the clinical routine when a 
child presents with febrile neutropenia, especially if any signs of respiratory symptoms are present. 
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Results positive for influenza, PIV, HMPV or RSV, together with respiratory symptoms, a negative 
blood culture, diagnosis and treatment phase of the patient, a low CRP level and a good general 
condition could be helpful in the decision to withdraw antibiotic treatment and discharge the patient 
after 48 hours. This is supported by a study conducted by Santolaya et al. (263). The authors stratified 
children after 48 hours with a positive respiratory viral finding, a negative blood culture, and favorable 
clinical evaluation (children excluded if they had a persistent fever, CRP ≥ 90 mg/L or hemodynamic 
instability) and then randomized these children to either continue the antimicrobials until the end of 
the febrile episode or withdrawal of treatment. The episodes resolved uneventfully in 95% of cases in 
which the antimicrobial treatment was withdrawn. In four cases in the withdrawal group, 
antimicrobial treatment was reinstated due to repeated fever, but no new bacterial infection or sepsis 
developed. The respiratory pathogens RV, EV, HCoV, HBoV, and HAdV could also be included in 
such a stratification but should be more cautiously interpreted as causative agents until more sensitive 
methods have been developed and hopefully introduced in the clinic. Similar studies on 
discontinuation of antibiotic treatment and early discharge have also been conducted; however, 
respiratory viral infections were not included in those stratifications (264, 265).  
   In addition, it would strengthen the risk prediction model of febrile neutropenia if we could identify 
genetic defects in proteins/enzymes important in the immune system that affect the risk of developing 
febrile neutropenia and MDI during these episodes. Unfortunately, in paper III, the results regarding 
MBL, TLR4, and IL-1Ra were not sufficient for model inclusion. However, additional investigations 
are requested, such as genome-wide association studies to identify novel proteins/enzymes associated 
with the risk of febrile neutropenia that later might be implemented as model predictors.  
 
4.3.2 How to evaluate a child with repeated or prolonged neutropenia and febrile 
neutropenia during cancer treatment 
When treating children with cancer, there is a fine balance between giving sufficient amounts of 
chemotherapy to eliminate the malignant cells without increasing the risks of severe side effects and 
secondary cancer (24). Neutropenia is a common condition during cancer treatment. However, how 
should children presenting with this condition be managed? The most common reason for neutropenia 
during treatment is as a chemotherapy side effect, however, only to a certain extent and it is not 
expected to be persistent. Other reasons for unexpected or prolonged neutropenia that need to be 
investigated are relapse of the disease or different infections (e.g., B19V) (85). After ensuring that 
relapse or infection is not the cause, other reasons, such as pharmacogenetic variables, are of great 
interest and need to be investigated further.  
   In this thesis, sequence variants in enzymes important for drug metabolism were investigated, with 
6-MP as a main focus. Importantly, signs of prolonged and otherwise unexplained neutropenia in 
children treated with 6-MP could be due to sequence variants in genes important for 6-MP 
metabolism. Evidence that both sequence variants in TPMT and NUDT15 affect the prescribed doses 
of 6-MP and increase the risk of myelosuppression were reported in several studies, but the role of 
ITPA is still not fully understood (Table 3). Dose adjustments according to TPMT genotype have been 
implemented during the last decade in many of the clinical treatment protocols for ALL but were only 
recently introduced for NUDT15 (162) Moreover, children with the combination of TPMT- and 
NUDT15-deficient genotypes seem to be more sensitive to 6-MP treatment with increased risk of 
myelosuppression (126, 266). In paper II, our results indicated that TPMT-deficient children had 
decreased risks of both neutropenia and febrile neutropenia during the maintenance II phase, which 
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was opposed to our hypothesis. However, we cannot fully explain these results and due to the small 
study cohort, future studies are needed to confirm these results. In addition, follow-up studies should 
also include evaluation of the relapse risk in deficient patients, as an increased risk of relapse has been 
reported after dose-adjustments for TPMT was implemented (148).  
   Why some children suffer from more frequent febrile neutropenia episodes has not yet to be fully 
understood. The sequence variants mentioned above could lead to an increased risk of neutropenia, 
and thereby increase the risk of febrile neutropenia. However, it could also be due to genetic variants 
in immune genes, making some patients more susceptible to infections. In paper III, we could 
identify that TLR4 deficient children had an increased risk of viral infections. However, the small and 
heterogeneous cohort made it difficult to draw any major conclusions. Nevertheless, it highlights that 
specific immune proteins or receptors probably play important roles in the development of different 
infections. The risk of developing both neutropenia and febrile neutropenia episodes during cancer 
treatment is probably due to multiple factors, both pharmacogenetic and immunological and the 
complexity of these factors need to be further investigated in order to properly evaluate children with 
frequent and prolonged neutropenia and febrile neutropenia episodes.    
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5 CONCLUSIONS 
Overall conclusions:  
(i) In many of the episodes of febrile neutropenia, the cause of the fever is still unknown. Even 
though respiratory viruses are common during febrile neutropenia episodes there is a need for 
development of additional more senstive methods to be able to identify and prove causality 
between the microbiological findings and the episode.  
(ii) Genetic variants in specific enzymes and proteins involved in drug metabolism and the 
immune system seem to play a role in the development of neutropenia, febrile neutropenia 
and infections during cancer treatment. However, some of these need to be further evaluated 
before modiciations of the management of febrile neutropenia could be recommended.  
 
Study specific conclusions:  
Paper I 
• Respiratory viral infections are common during episodes of febrile neutropenia, and most 
virus are cleared within a few weeks after the initial finding. This strengthens the evidence 
that respiratory viruses are the cause of febrile neutropenia episodes, however casuality could 
not be proven in paper I.   
Paper II 
• Sequence variants in TPMT and ITPA (rs1127345) were identified to decrease the risk of 
febrile neutropenia in our study. However, due to the complexicity of 6-MP metabolism and 
the small study cohort, it is still not fully understood how these genetic variants affect the risk 
of febrile neutropenia.  
• Children with NUDT15 genetic variants recieved lower 6-MP end doses in our study. 
NUDT15 deficiency seem to play a role during 6-MP tretment. However, the analysis and 
conclusions of our study is limited by the low prevalence of NUDT15 in the cohort. 
Paper III 
• Viral infections are the most common microbiological findings during febrile neutropenia 
episodes in pediatric ALL patients. However, the majority of the episodes were defined as 
FOU.  
• Sequence variants in the genes encoding TLR4 and IL-1Ra seem to alter the infection risk 
during febrile neutropenia episodes during pediatric ALL treatment. However, further 
investigation to evalute these findings is needed.   
Paper IV 
• Based on our results, gene-expression profiling is not a suatible diagnostic tool for detection 
of pathogens in children treated for cancer. The low number of immune cells in these 
children, and the corresponding low amount of RNA for analysis, hinder the assessment of 
specific innate transcriptional pathways in blood.  
• Respiratory viruses’ role as an etiologial agent could not be directly correlated to febrile 
neutropenia episodes by using gene-expression profiling from blood.  
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6 FUTURE PERSPECTIVES 
As the survival rate continues to increase during cancer treatment, it is important to develop a proper 
strategy for the severe side effects sometimes related to treatment, such as febrile neutropenia. Some 
challenges remain in the management of children presenting with febrile neutropenia. First, all the 
episodes during treatment are not fully characterized with all the different microbiological agents in 
focus. Therefore, a proper prospective study investigating bacteria, viruses, and fungi with 
microbiology testing and clinical evaluation of the detected pathogens would be of great interest.  
   Antibiotic treatment is definitely essential during febrile neutropenia episodes; however, the issue of 
antibiotic resistance has emerged in the past decade (35, 36). As with all drugs, antibiotic treatment 
has side effects such as an increased risk of subsequent infections with resistant bacteria and 
complicated IFD (71, 72). In addition, intravenous antibiotic treatment necessitates in-hospital care in 
most cases. This highlights the second challenge during febrile neutropenia: the current methods for 
pathogen detection need improvement due to both low sensitivity (blood cultures in pediatric patients) 
and specificity (PCR) that make it difficult to rely on these results in a clinical setting. If a prospective 
study investigating the different microbiological agents during febrile neutropenia were to be 
performed, the method used in Paper IV (RNA sequencing) should be included. However, samples 
from relevant mucosal sites should be collected to further understand the immune response to 
pathogens in this patient cohort, with the main focus on respiratory viruses. Then, if specific 
signatures for the local response could be identified, this could help guide the management of these 
patients. Still, RNA sequencing is a rather time consuming and costly method, and more rapid and 
cost-effective methods are needed to have an impact on clinical management. PCR has been presented 
to validate the results from sequencing methods, and it is both time saving and can be performed at a 
relatively low cost (231, 267). Gómes-Carabella et al. developed a reverse transcription-PCR to test 
and validate the two structures (IFI44L and FAM89A) identified by Herberg et al. to distinguish 
bacterial from viral infections in febrile children and healthy controls (230, 267). However, the local 
response in immunosuppressed patients need to be evaluated first before similar studies could be 
performed.  
   With the new emerging SARS-CoV-2, there has been an increased interest in the role of respiratory 
viruses. For how long are respiratory viruses abundant in the host after primary infection? Is there 
such an entity as asymptomatic infections? For how long are the viruses contagious? Because of this 
new virus, I think and hope that the role of respiratory viruses will be better characterized and 
investigated to establish their role as infectious pathogens. Gene-expression analysis for respiratory 
viruses will be of great interest, both samples taken from the nasal cavity as well as the blood in order 
to be able to differentiate an active infection from a viable virus from viral remnants or asymptomatic 
infections. SARS-CoV-2 has not yet been reported as a major risk in children treated for cancer. 
However, to date, the role of SARS-Cov-2 is not comprehensively evaluated in this patient cohort.  
   The third challenge is that additional information regarding the risk of developing febrile 
neutropenia needs to be further evaluated. Within the pharmacogenetic field, certain enzymes increase 
the risk of side effects (e.g., TPMT and NUDT15) and therefore have been implemented in treatment 
protocols. However, similar proteins in the immune system have not been discovered and 
implemented to the same extent, but hypothetically, there are factors that indeed affect the child’s risk 
of febrile neutropenia. Genome-wide association studies could be useful here, but only one such study, 
by Lund et al, has been performed in a smaller cohort of children with febrile neutropenia in the 
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Nordic countries (185). However, as the results are difficult to interpret and confounders difficult to 
properly control for, larger cohorts with sufficient clinical data during the febrile neutropenia episodes 
are needed for such studies. If genetic defects in important immune proteins could be identified as risk 
factors, they could be used as predictive values for a better risk stratification model during febrile 
neutropenia. Such an algorithm could be evaluated in a study similar to Santolaya et al. but in a 
Nordic context to assess the safety of withdrawing antibiotic treatment during febrile neutropenia 
episodes (263). If microbiological pathogen detection, together with a proper febrile neutropenia risk 
stratification could be developed, this information would be of great clinical use to decrease broad-
spectrum antibiotic use and time of in-hospital care. This in turn could lead to decreased risk of 
infections with resistant bacteria and improved quality of life in this patient cohort.  
   In summary, treatment of the different cancer diagnoses is increasingly individualized, with the goal 
to give patients just the “right amount” of chemotherapy –– sufficient to cure the disease while 
causing minimal side effects. The same approach should also be applied during febrile neutropenia 
episodes in that all children should be stratified according to a febrile neutropenia risk group and 
managed in a more individualized manner. Hopefully, this scenario is clinically implemented within a 
few years. To reach this goal, more research within the field of febrile neutropenia during cancer 
treatment is needed.   
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Överlevnaden för barn som behandlas för cancer har ökat under de senaste decennierna och är idag 
över 80%. Detta beror bland annat på nya läkemedel och en mer individualiserad behandling. Många 
barn upplever dock fortfarande biverkningar p.g.a. behandlingen, där ett lågt antal vita blodkroppar (så 
kallad neutropeni) och neutropen feber (neutropeni tillsammans med feber) är en allvarlig biverkning 
från cellgifter. När neutrofilerna sjunker till under 0,5 x 109/L, ökar risken för infektioner kraftigt. 
Trots att infektionsdödligheten har sjunkit i den här gruppen orsakar den långa inneliggande 
sjukhusperioder och många dagars behandling med bredspektrumantibiotika. Att kunna identifiera 
vilka agens som orsakar neutropen feber och vilka riskfaktorer det finns för att drabbas av neutropen 
feber skulle kunna användas i kliniken för att individualisera behandlingen för barn som behandlas för 
cancer. Det skulle i längden kunna leda till minskad tid på sjukhus och kortare behandling med 
bredspektrumantibiotika, vilket i sin tur skulle ha positiva sociala effekter på barnen och deras familjer 
såväl som minska risken för att drabbas av resistenta bakterier. Min avhandling har därför haft två 
huvudfokus: Att undersöka etiologin till neutropen feber hos barn med cancer (delstudie I och IV) 
och att undersöka genetiska riskfaktorer för att drabbas av neutropeni och neutropen feber (delstudie 
II och III).  
 
Etiologi till neutropen feber hos barn som behandlas för cancer 
Luftvägsvirus är ett av de vanligaste mikrobiologiska fynden vid neutropena feberepisoder hos barn 
som behandlas för cancer vid användning av molekylärbiologiska metoder (så kallad ”polymeras 
chain reaction” (PCR)). Luftvägsvirus hittas i 44-52% av alla episoder, vilket också kunde bekräftas i 
vår delstudie I där luftvägsvirus identifierades som det vanligaste fyndet vid neutropen feber (45%). 
Det som skiljer vår studie från tidigare studier var att vi också tog uppföljningsprov på alla 
viruspositiva barn och vi kunde då se att de flesta hade icke-detekterbara nivåer av virus efter ett par 
veckor. De virus som fortfarande hittades vid uppföljning var rhinovirus och coronavirus, två av de 
vanligaste förkylningsvirusen. Resultaten styrkte vår tes att luftvägsvirus är en vanlig orsak till 
neutropen feber i denna patientgrupp, men vi hade fortfarande svårt att fastslå att det förelåg ett 
orsakssamband.  
   Delstudie IV var därför en uppföljningsstudie på delstudie I, med samma grupp av patienter, men 
där vi tittade på det immunologiska svaret i blod istället för de vanliga diagnostiska metoderna. 
Genom att använda RNA-sekvensering, en metod som gör det möjligt att mäta allt RNA vid ett 
specifikt tillfälle, kunde vi indirekt studera vilka gener som var aktiverade vid en specifik tidpunkt. 
Detta gjordes för att undersöka om vi kunde hitta specifika immunsignaturer i blodet vid olika typer 
av infektioner. Sådana specifika signaturer finns beskrivna hos immunfriska barn med feber, men det 
var fortfarande oklart om barn med cancer som genomgår immunosupprimerande behandling också 
uttrycker liknande svar. Tyvärr upptäcktes två problem med att använda denna metod i delstudie IV: 
Det första var att i över 30% av alla episoder med neutropen feber fanns det för få celler i blodet för att 
kunna generera något mätbart RNA. Det andra var att i de fall där det faktiskt fanns tillräckligt med 
RNA i blodet så kunde vi inte identifiera några specifika immunsignaturvägar vid olika typer av 
infektioner. Slutsatsen blev därför att det i nuläget är svårt att använda en sådan metod hos barn som 
behandlas för cancer.  
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Riskfaktorer till neutropeni och neutropen feber hos barn som behandlas för akut leukemi 
Alla barn som behandlas för akut lymfatisk leukemi (ALL) i Sverige följer samma 
behandlingsprotokoll, vilket betyder att de får ungefär samma mängder med cellgifter. Trots detta 
drabbas vissa barn av både fler och allvarligare biverkningar och infektioner än andra, vilket gör att 
man tror att vissa barn har en predisponerad benägenhet att drabbas. Orsaken till detta skulle kunna 
vara genetiska varianter i viktiga enzymer eller proteiner i läkemedelsmetabolismen och/eller 
immunförsvaret. Läkemedlet 6-Mercaptopurine (6-MP) är ett av de vanligaste immunosupprimerande 
läkemedlen som används för behandling av ALL och ges nästan varje dag under 2,5 års behandling. I 
delstudie II undersöktes genetiska förändringar i gener viktiga i 6-MP läkemedelsmetabolismen 
såsom TPMT, NUDT15 och ITPA och deras roll för neutropeni, neutropen feber och slutdoser av 6-
MP. Vi kunde identifiera att barn med varianter i TPMT-genen hade en minskad risk att drabbas av 
neutropeni och neutropen feber under den sista delen av ALL behandlingen och barn med genetiska 
förändringar i ITPA (en av de två undersökta varianterna) hade en minskad risk att drabbas av 
neutropen feber under hela behandlingstiden. Vi upptäckte också att barn med genetiska förändringar i 
NUDT15 hade lägre slutdoser av 6-MP. Trots våra resultat är det fortfarande oklart vad genetiska 
förändringar i TPMT och ITPA spelar för roll i utvecklingen av neutropen feber hos barn som 
behandlas för cancer. Däremot verkar NUDT15 ha en viktig roll vid behandling med 6-MP. Det 
behövs mer studier inom ämnet med större patientgrupper för att kunna dra säkrare slutsatser.  
   Att hitta riskfaktorer för att drabbas av neutropen feber och infektioner såsom virus, bakterier eller 
svamp skulle kunna leda till att behandlingen blir mer individualiserad. I delstudie III karaktäriserade 
vi de mikrobiologiska fynd som rapporterats under episoderna av neutropen feber under hela ALL-
behandlingen och undersökte om genetiska förändringar i viktiga proteiner i det medfödda 
immunsystemet, såsom MBL, TLR4 och IL-1Ra påverkade risken för att drabbas. Vi kunde 
rapportera att virusinfektioner var det vanligaste fyndet under neutropena feberepisoder. Det slående 
var dock att i ca 60% av alla episoder rapporterades ingen infektiöst orsak under episoden. I de 
genetiska analyserna identifierades att två specifika förändringar i TLR4 genen ökade risken för att 
drabbas av virusinfektioner och att genetiska förändringar i IL-1Ra minskade risken att drabbas av 
bakteriella infektioner. Sammanfattningsvis är virusinfektioner vanliga vid neutropena feberepisoder, 
men i majoriteten av episoderna hittas ingen orsak till febern. Även om det i vår studie pekade på att 
TLR4 och IL-1Ra påverkar risken att drabbas av olika infektioner, är det fortfarande inte tillräckligt 
för att ändra några rekommendationer och hitta patienter som är specifikt i riskzon för att drabbas. 
Ytterligare studier, både med fokus på diagnostik för att hitta orsaken till febern samt andra 
riskfaktorer för att drabbas behövs. 
 
Slutsats 
Ett av problemen som kvarstår är att det fortfarande i många episoder inte hittas någon orsak till 
neutropena feberepisoden. Luftvägsvirus är ett vanligt fynd vid neutropen feber, men vi kunde inte 
genom våra metoder visa att det fanns ett orsakssamband mellan virusfyndet och neutropena 
feberepisoden. Därför behövs det fler och mer känsliga metoder för att kunna sammankoppla 
mikrobiologiska fynden med den aktuella episoden. Genetiska varianter i enzymer och proteiner i 
läkemedelsmetabolismen och immunförsvaret verkar spela roll i utvecklingen av neutropen feber och 
infektioner. Men dessa behöver utredas vidare innan man kan använda den informationen i kliniken 
för att guida handläggningen av neutropena feberepisoder.  
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